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A B S T R A C T
Glial cell line-derived neurotrophic factor (GDNF) is widely recognized as a potent survival factor for
dopaminergic neurons of the nigrostriatal pathway that degenerate in Parkinson’s disease (PD). In animal
models of PD, GDNF delivery to the striatum or the substantia nigra protects dopaminergic neurons
against subsequent toxin-induced injury and rescues previously damaged neurons, promoting recovery
of the motor function. Thus, GDNF was proposed as a potential therapy to PD aimed at slowing down,
halting or reversing neurodegeneration, an issue addressed in previous reviews. However, the use of
GDNF as a therapeutic agent for PD is hampered by the difficulty in delivering it to the brain. Another
potential strategy is to stimulate the endogenous expression of GDNF, but in order to do that we need to
understand how GDNF expression is regulated. The aim of this review is to do a comprehensive analysis
of the state of the art on the control of endogenous GDNF expression in the nervous system, focusing
mainly on the nigrostriatal pathway. We address the control of GDNF expression during development, in
the adult brain and after injury, and how damaged neurons signal glial cells to up-regulate GDNF.
Pharmacological agents or natural molecules that increase GDNF expression and show neuroprotective
activity in animal models of PD are reviewed. We also provide an integrated overview of the signalling
pathways linking receptors for these molecules to the induction of GDNF gene, which might also become
targets for neuroprotective therapies in PD.
 2008 Elsevier Ltd. All rights reserved.
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GDNF expression
The slow and progressive loss of dopaminergic neurons from
the substantia nigra in Parkinson’s disease (PD) makes it amenable
to treatments that protect the remaining dopaminergic neurons
and/or prevent the death of injured ones. This issue becomes an
important challenge when the effectiveness of the most potent
symptomatic treatment for PD, the administration of the
dopamine precursor L-DOPA (L-3,4-dihydroxyphenylalanine),
decreases over time and patients start to develop disabling side
effects (reviewed by Lim, 2005). Therefore, the search for new
symptomatic treatments, as well as for neuroprotective and
neurorestorative strategies is currently underway (reviewed by
Wu and Frucht, 2005).
Neurotrophic factors have emerged as key factors in the
survival and phenotypic differentiation of neuronal cells during
development, in the maintenance of mature neurons in the adult
brain, as well as in their protection/repair upon injury (Benn and
Woolf, 2004). It was proposed that changes in the levels of
neurotrophic factors, due to alterations in the synthesis, release or
activity associated with ageing or genetic factors, might be
involved in the neuronal loss observed in neurodegenerative
diseases as PD (reviewed by Siegel and Chauhan, 2000; Mattson
and Magnus, 2006). In fact, brain-derived neurotrophic factor
(BDNF) mRNA (Howells et al., 2000) and protein levels (Mogi et al.,
1999; Parain et al., 1999), as well as nerve growth factor (NGF)
levels (Mogi et al., 1999) are reduced in PD substantia nigra. Large
reductions in basic fibroblast growth factor (bFGF or FGF-2)
content were reported in surviving PD substantia nigra neurons
(Tooyama et al., 1993), while no differences were found in the
striatal levels between controls and PD patients (Mogi et al., 1996).Concerning glial cell line-derived neurotrophic factor (GDNF), post-
mortem studies investigating its distribution in the human
parkinsonian brain have yielded conflicting results (Hunot et al.,
1996; Chauhan et al., 2001; Mogi et al., 2001). Since GDNF
expression is reduced in the adult brain, the use of techniques that
enhance the detection of low copy mRNA transcripts may be
crucial for accurate quantification of its expression. Recently, using
real-time PCR, Backman et al. (2006) described the GDNF isoform II
as the predominant transcript in the putamen of human subjects,
whereas only the expression of GDNF isoform I is modestly
increased in the putamen of PD patients with marked nigral
neuronal loss (Backman et al., 2006).
Despite the conflicting results on neurotrophic factor levels in
the striatum and substantia nigra in PD, it has been suggested that
the replacement of such factorsmay prevent the progression of the
disease (Levy et al., 2005). GDNF is a promising therapeutic agent
for the treatment of neurodegenerative diseases, in particular PD.
In fact, many studies in animal models (reviewed by Soderstrom
et al., 2006) and some studies in PD patients show that GDNF
delivery can have trophic effects and restore motor function (Gill
et al., 2003; Slevin et al., 2005), although some problems need to be
overcome before GDNF therapy for PD becomes a reality (Sherer
et al., 2006). For instance, the delivery of GDNF to the central
nervous system (CNS) is challenging because GDNF is unable to
cross the blood–brain barrier (Kastin et al., 2003; Kirik et al., 2004).
A possibility to overcome this limitation is to conjugate or fuse
GDNF with other molecules that enable it to cross the blood–brain
barrier. Fusion with viral proteins, conjugation with antibodies for
transferrin or insulin receptors, or with a fragment of the tetanus
toxin have been demonstrated to provide an efficient way of
delivering GDNF to the CNS (Albeck et al., 1997; Dietz et al., 2006;
Larsen et al., 2006; Boado et al., 2007; Xia et al., 2008). Molecules
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to be an alternative therapeutic option for PD. Interestingly, it was
suggested thatXIB4035, a non-peptidyl smallmolecule that acts as a
GDNF family receptor (GFR)a1agonist andmimics theneurotrophic
effects of GDNF in Neuro-2A cells, might have beneficial effects for
the treatment of PD (Tokugawa et al., 2003). More recently, the oral
administration of PYM50028, a novel non-peptide neurotrophic
factor inducer, to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-lesioned mice resulted in a significant elevation of striatal
GDNF and attenuated the loss of dopaminergic neurons from the
substantia nigra (Visanji et al., 2008).
Finding molecules like XIB4035 or PYM50028, capable of
stimulating GDNF expression/signaling, may prove beneficial to
the treatment of PD. The development of small molecules that
specifically activate the GDNF receptor and can be administered
systemically would overcome most of the problems associated
with the delivery of GDNF protein into the brain, with GDNF
expression induced by viral vectors, or with the use of
encapsulated GDNF producing cells (Bespalov and Saarma,
2007). In addition, or as an alternative, pharmacological stimula-
tion of endogenous GDNF synthesis using low-molecular weight
drugs capable of activating GDNF expression is another potential
choice for the treatment of PD. To accomplish that, however, it is
necessary to understand the regulation of GDNF expression in
order to identify therapeutic targets able to modulate endogenous
GDNF expression and release.
The aim of the present work is to review and integrate the
available data on the control of the endogenous expression of
GDNF, both in physiological conditions (during development and
normal activity of the nervous system) and upon brain injury,
focusing mainly on the nigrostriatal system. The communication
between neurons, astrocytes, andmicroglial cells will be addressed
to identify intercellular signals that regulate GDNF expression and/
or release. The large number of compounds, both endogenous and
pharmacological agents, found to trigger or modulate GDNF
expression will be described. An overview of the signalling
pathways leading to the regulation of GDNF gene transcription
will also be presented. To our knowledge, the present review is the
first one attempting a comprehensive analysis of the control of
GDNF expression in the nervous system.
2. GDNF role in the nervous system
2.1. GDNF: identification and characterization
GDNF was identified and purified from the B49 glioma cell line
based on its ability to promote the survival of dopaminergic
neurons in dissociated rat mesencephalic cultures, and to increase
their neurite length and cell size, as well as the high affinity
dopamine uptake, without significantly affecting non-dopaminer-
gic neurons or glial cells (Lin et al., 1993). GDNF is a glycosylated,
disulfide-bonded homodimer, with a molecular weight of 33–
45 kDa, while themonomer has amolecular weight of 16 kDa after
deglycosylation (Lin et al., 1994). Sequence data suggest that GDNF
is synthesized as an inactive 211 amino acids-long pre-proGDNF,
and then processed to the mature protein with 134 amino acids
(Lin et al., 1993).
GDNF is the founding member of the GDNF family of
neurotrophic factors, which additionally includes three other
structurally related members, neurturin (Kotzbauer et al., 1996),
persephin (Milbrandt et al., 1998), and artemin (Baloh et al., 1998).
Themembers of theGDNF family belong to the transforminggrowth
factor (TGF)-b superfamily because they contain seven cysteine
residues in the same relative spacing as the other members of the
superfamily, despite the a low sequence homology (Lin et al., 1993).GDNF family ligands signal through a multicomponent
receptor complex comprising the transmembrane Ret tyrosine
kinase and a member of a family of glycosylphosphatidylinositol
(GPI)-anchored cell surface proteins, the GFRa. To date, four
members of this family have been identified (GFRa1–4), the
preferential binding occurring between GDNF and GFRa1,
neurturin and GFRa2, artemin and GFRa3, and persephin and
GFRa4. In the Ret/GFRa receptor complex, ligand binding is
performed by the GFRa and the intracellular signalling by Ret.
Additionally, there is a Ret-independent signalling pathway, using
GFRa1-associated Src kinase activation, and GFRa has been
shown to use also neural cell adhesion molecules (NCAM) as
signalling receptors for GDNF family ligands (reviewed by Sariola
and Saarma, 2003). In addition to the known receptors GFRa1 and
Ret, GDNF signalling requires heparan sulphate glycosaminogly-
cans (reviewed by Sariola and Saarma, 2003), but recent findings
suggest that the contribution of heparin and heparan sulphate
does not occur during the GDNF–GFRa1 engagement (Alfano
et al., 2007). An evidence for the involvement of heparan sulphates
in GDNF signalling comes also from studies showing that a
marine-derived acidic oligosaccharide activates GDNF signalling
as assessed by Ret phosphorylation and neurite outgrowth in
PC12-treated cells (Wang et al., 2007). Other recent finding
suggests that integrin b1, an other adhesion molecule, is also
involved in GDNF signalling (Cao et al., 2008).
2.2. CNS distribution
Using in situ hybridization and reverse transcription-PCR,
GDNF transcripts were identified in many different regions of the
developing and adult brain, as well as in peripheral tissues,
indicating that GDNF may have multiple actions. In the rat
nervous system, GDNF mRNA is present in the thalamus,
hippocampus, cerebellum, cortex, striatum, and spinal cord
(Stromberg et al., 1993; Choi-Lundberg and Bohn, 1995; Pochon
et al., 1997; Trupp et al., 1997). In the rat striatum, GDNFmRNA is
present at highest levels during early postnatal development
(Schaar et al., 1993; Stromberg et al., 1993; Blum and Weickert,
1995; Choi-Lundberg and Bohn, 1995), and GDNF protein is also
present in the striatum early in the development (Lopez-Martin
et al., 1999; Oo et al., 2005). In adult rats, the levels of GDNFmRNA
are significantly higher in the ventral striatum than in the dorsal
striatum (Barroso-Chinea et al., 2005). The levels of GDNF mRNA
in the substantia nigra are much lower than in the striatum (Choi-
Lundberg and Bohn, 1995; Oo et al., 2005), which suggests a role
for GDNF mainly as a target-derived neurotrophic factor for
dopaminergic neurons. In fact, after intrastriatal injection in adult
rats, both unlabelled and 125I-labelled GDNF are transported to
dopaminergic cell bodies in the substantia nigra pars compacta,
suggesting that in the adult nigrostriatal system GDNF acts
endogenously as a target-derived factor for dopaminergic
neurons (Tomac et al., 1995). Going further, Barroso-Chinea
et al. (2005) reported that the ventral tegmental area (VTA) and
the rostromedial substantia nigra (SNrm) contain GDNF but not
GDNF mRNA. Immunocytochemistry studies performed after
colchicine injection in the lateral ventricle show that VTA and
SNrm cells are immunonegative for GDNF, suggesting that GDNF
in dopaminergic soma comes from their striatal target (Barroso-
Chinea et al., 2005), an observation consistent with previous
findings. In the adult human CNS, GDNF mRNA is detected in the
striatum, hippocampus, cortex, and spinal cord (Springer et al.,
1994).
Northern blot, PCR, and in situ hybridization analysis detect
GFRa1 and Ret inmanyGDNF-responsive regions of the embryonic
and adult rat nervous system, including in the dopaminergic
A. Saavedra et al. / Progress in Neurobiology 86 (2008) 186–215 189neurons from the substantia nigra (Treanor et al., 1996; Nosrat
et al., 1997; Trupp et al., 1996, 1997).
Altogether, these findings suggest a role for GDNF in the target-
derived support of dopaminergic neurons, and the potential
involvement in the support of other neuronal populations. Indeed,
although first described as a selective neurotrophic molecule for
nigral dopaminergic neurons in vitro, other central and peripheral
nervous system neurons, including spinal motoneurons, sympa-
thetic and sensory neurons, are responsive to GDNF (Henderson
et al., 1994; Arenas et al., 1995; Buj-Bello et al., 1995; Trupp et al.,
1995; Hearn et al., 1998; Heuckeroth et al., 1998).
GDNFmRNA isalsowidely expressedoutside thenervous system
in developing rats, including in kidney, lung, stomach, gonads, and
skin (Suter-CrazzolaraandUnsicker, 1994;Truppetal., 1995). This is
consistent with GDNF having several roles outside the nervous
system. These include its action as a morphogen during kidney
development (reviewed by Costantini and Shakya, 2006), as mice
lacking GDNF do not have kidneys (Moore et al., 1996; Pichel et al.,
1996; Sanchez et al., 1996), or in the regulation of spermatogenesis
(Naughton et al., 2006 and references therein).
2.3. Role of GDNF in the development and maintenance of the
nigrostriatal system
Since GDNF was identified as a trophic factor for dopaminergic
neurons (Lin et al., 1993), it was surprising to find that newborn
mice deficient for GDNF, GFRa1, or Ret showed no apparent
deficits in midbrain dopaminergic neurons (reviewed by Enomoto,
2005). However, due to the absence of enteric neurons and
kidneys, these mice die soon after birth, whereas the develop-
mental programmed cell death of dopaminergic neurons from the
substantia nigra occurs later on postnatal life. This event has a
biphasic time-course, with an initial peak on postnatal day 2, and a
second one on postnatal day 14 (Burke, 2003). In fact, GDNF
selectively supports the viability of postnatal nigral dopaminergic
neurons in culture by preventing apoptosis with both regional
specificity for the substantia nigra vs. VTA, and cellular specificity
for the dopaminergic phenotype (Burke et al., 1998).
To be able to examine the role of GDNF in the development of
the dopaminergic nigrostriatal system and overcome the limita-
tion produced by the death soon after birth of GDNF-deficient
mice, Granholm et al. (2000) transplanted foetal dopaminergic
neurons from the ventral mesencephalon of GDNF/, GDNF+/,
and wild-type mice into the dopamine-denervated striatum of
adult wild-typemice. Using this approach, they demonstrated that
the postnatal development of dopaminergic neurons is severely
disturbed in the absence of GDNF, as shown by the markedly
reduced number of dopaminergic neurons and fibre outgrowth,
indicating that GDNF is required for postnatal maturation of
midbrain dopaminergic neurons. The hypothesis that GDNF is a
limiting striatal target-derived neurotrophic factor for developing
substantia nigra dopaminergic neurons is also supported by the
observation that the intrastriatal administration of GDNF during
the period of ontogenetic cell death suppresses apoptosis of nigral
dopaminergic neurons (Oo et al., 2003). Furthermore, neutralizing
endogenous GDNF by the application of GDNF antibodies to the
striatum enhances cell death during the first period of cell death
(Oo et al., 2003). More recently, in a double transgenic mouse
model, it was shown that selective GDNF overexpression in the
striatum throughout the development increases the number of
surviving dopaminergic neurons in the substantia nigra following
the first phase of cell death (Kholodilov et al., 2004).
Although neurochemical and behavioural measures suggested
that reduction of GDNF gene expression in the GDNF+/ mutant
mice does not alter the nigrostriatal dopaminergic system, andtherefore that endogenous GDNF may not be critical for the
development and functioning of the nigrostriatal dopaminergic
system (Gerlai et al., 2001), more recent studies point towards the
opposite direction. Using a conditional GDNF-null mouse to
suppress GDNF expression in the adult, Pascual et al. (2008)
clearly demonstrate that GDNF is crucial for adult catecholami-
nergic neuronal survival. After GDNF ablation, mice showed a
progressive hypokinesia and a selective decrease of brain tyrosine
hydroxylase (TH) mRNA, together with a specific and extensive
catecholaminergic neuronal death, affecting most notably the
locus coeruleus, the substantia nigra and the VTA. The importance
of GDNF for the development and maintenance of the nigrostriatal
pathway is also strengthened by findings showing that Ret-
deficient mice present progressive and adult-onset loss of
dopaminergic neurons specifically in the substantia nigra pars
compacta, degeneration of dopaminergic nerve terminals in the
striatum, and pronounced glial activation (Kramer et al., 2007).
Furthermore, temporary blockade of Ret expression in embryos
using Ret antisense oligonucleotides (Ret-AS-ODN) leads to
reduced striatal dopamine content and a decrease in TH positive
fibres in the striatum. Additionally, some dopaminergic neurons in
the substantia nigra undergo apoptotic cell death following the Ret-
AS-ODN treatment suggesting that normal function of Ret is
required in vivo for the maturation of dopaminergic neurons, for
cell survival and fibre innervation (Li et al., 2006b).
A role for GDNF in modulating the pattern of dopaminergic
innervation is also suggested by results obtainedwith rat postnatal
organotypic slice co-cultures prepared from substantia nigra,
striatum and cortex since addition of GDNF to these cultures
increases the number of dopaminergic neurons, and the number of
dopaminergic processes innervating the striatum (Jaumotte and
Zigmond, 2005). Using organotypic cultures from the ventral
mesencephalon of GDNF-deficient mice, Bjerken et al. (2007)
observed also that although midbrain dopaminergic neurons from
GDNF knockout mice survive in the absence of GDNF, the addition
of GDNF increased nerve fibre outgrowth possibly because of the
augmented astrocytic stimulation observed in the presence of
GDNF in these cultures. Moreover, GDNF levels seem to be crucial
to the maintenance of dopaminergic neurons during the ageing
process since the age-related decrease in substantia nigra TH
immunostaining observed in wild-type mice is accelerated in
GDNF+/ mice (Boger et al., 2006).
Altogether, these studies strongly suggest that GDNF plays an
essential role in the development of the dopaminergic nigrostriatal
system, and that even a slight disturbance in the make-up of this
system due to GDNF deficits might compromise dopaminergic
survival in the adulthood.
3. Control of GDNF expression during development
Despite the advances in understanding the role of GDNF in the
development and maintenance of the nigrostriatal system, our
knowledge of how GDNF expression is regulated during these
processes is still in a very embryonic stage. Very recently, it was
described that the overexpression of Pitx3 in SH-SY5Y cells and
primary ventral mesencephalic cultures significantly increases
GDNF and BDNF mRNA levels and elevates their protein levels
(Peng et al., 2007). Since Pitx3 is a transcription factor with an
important role in the growth and differentiation of dopaminergic
neurons (reviewed by Smidt et al., 2004) this finding may
represent the very first step, as far as we are aware, for unravelling
how GDNF expression is regulated during the development of the
nigrostriatal system.
In contrast, the regulation of GDNF expression during kidney
development is much better understood. GDNF signalling through
Table 1
Positive and negative regulatory molecules on GDNF expression/signalling during
kidney development
Positive regulatory factors Negative regulatory factors
Six1 Foxc1
Six2 Foxc2
Pax2 Slit2/Robo2
Eya1 BMP4
Sall1 Sprouty1
Growth/differentiation factor 11
Hox11
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bud during kidney development, and GDNF is the growth factor
most extensively implicated in ureteric bud branching morpho-
genesis (reviewed by Costantini and Shakya, 2006). The key role of
GDNF and its receptors in kidney development was initially
revealed by the targeted gene disruption of GDNF, Ret, or GFRa1
(reviewed by Enomoto, 2005). Further evidence for the importance
of GDNF has come from the study of molecules found to regulate,
positive or negatively, the level, timing or spatial extent of GDNF
expression during kidney development (Table 1). Mutations in the
genes encoding those molecules result in abnormalities due to
altered GDNF expression (reviewed Bouchard, 2004; Costantini
and Shakya, 2006).
A great deal of information on the regulation of GDNF
expression during development comes from studies on the
developing kidney. This is because, with few exceptions, many
genes that play a crucial role in early kidney development, such as
Pax2, Eya1, Six1, Six2, Sall1, Foxc1, Wt1, and the Hox11 genes,
encode transcription factors that, organized in a complex network,
are involved in the regulation of GDNF gene (Brodbeck and Englert,
2004).
Some studies point to a possible activation of the GDNF gene by
the transcription factors Six1 and Six2 (Xu et al., 1999;Wellik et al.,
2002). In fact, chromatin immunoprecipitation and microinjection
assays reveal binding and activation of GDNF intron 1 by the Six1
protein (Li et al., 2003), and Six4 seems to cooperatewith Six1 in the
metanephric mesenchyme to regulate the level of GDNF expression
(Kobayashi et al., 2007). Six2 also activates GDNF expression, and
two Six2 binding sites in the GDNF promoter were identified
(Brodbeck et al., 2004). The activation complex of GDNF may also
include the Pax2 protein, since Pax2 binds to the 50-untranslated
region of GDNF exon 1, and can transactivate the expression of
reporter genes, which can explain the observation that GDNF
expression ismissing inPax2knockout animals (Brophyetal., 2001).
Knockoutmice for the transcriptional regulator Eya1 show lossof
GDNF expression (Xu et al., 1999). However, it is unlikely that the
effect of Eya1onGDNF isdirect since Eya1needsamemberof the Six
protein family for nuclear translocation (Ohto et al., 1999). In fact,
Eya1 probably functions at the top of the genetic hierarchy
controlling kidney organogenesis, acting as a key regulator for
GDNF expression during metanephric induction, and interacting
withSix1andPax2 to regulate theureteric outgrowthandbranching
(Sajithlal et al., 2005). The homeodomain transcription factor Sall1
also seems to play a role in GDNF regulation since in the absence of
Sall1, the levels of GDNF are reduced, which correlates with an
incomplete ureteric bud outgrowth (Nishinakamura et al., 2001).
However, the deletion of a signalling molecule encoding the
TGF-b family member growth/differentiation factor 11 can also
result in loss of GDNF expression (Esquela and Lee, 2003). Many
genes crucial to kidney development are evolutionarily conserved,
and correspond to orthologous genes that regulate eye develop-
ment in Drosophila. It should also be stressed that many of these
genes are involved in the formation of more than one organ(reviewed by Brodbeck and Englert, 2004), so it might therefore be
worthy to investigate them for a possible role on the control of
GDNF expression during the development of the nigrostriatal
system.
In addition to these positive regulatory factors, evidence for
factors that can down-regulate GDNF expression during kidney
development is also available. Mouse knockout studies have
identified two negative regulatory mechanisms that modulate
GDNF expression during urogenital development. Deletion of the
transcription factors FoxC1 and FoxC2 causes an anterior expan-
sion of GDNF expression, implying that these factors normally
restrict the domain of GDNF expression (Kume et al., 2000). Other
studies have identified a different signalling system that is also
required to limit the regional GDNF expression, the secreted factor
Slit2 and its receptor Robo2. Knocking out Slit2 or Robo2 results in
a slight anterior expansion of the GDNF expression, and thus the
Robo2/Slit2 pathway defines the anterior boundary of the
metanephric mesenchyme (Grieshammer et al., 2004). Additional
negative regulators of Ret/GDNF signalling include the bone
morphogenic protein (BMP) 4, and Sprouty1. BMP4 suppresses the
effects of ectopic GDNF in vitro (Brophy et al., 2001), and loss of the
receptor tyrosine kinase antagonist Sprouty1 causes defects in
kidney development in mice due to increased sensitivity of the
Wolffian duct to GDNF/Ret signalling, which induces super-
numerary ureteric buds (Basson et al., 2005). However, neither
Sprouty nor BMP4 affect the GDNF expression pattern.
4. Neurotransmitters affecting GDNF expression
Afferent activity regulates the expression of neurotrophic
factors (Hughes et al., 1999) and therefore dopamine is a likely
candidate to control GDNF expression in the nigrostriatal system
(Fig. 1). In line with this, mice lacking D2 receptors (D2R/) show
reduced levels of GDNF in the striatum (Bozzi and Borrelli, 1999).
Also in agreementwith these data, D1 and D2 agonists increase the
synthesis of GDNF in mesencephalic and striatal neuronal cultures
(Guo et al., 2002), and in astroglial cultures (Ohta et al., 2000, 2003,
2004). Exposure to dopamine, apomorphine, or the specific D1
agonist SKF-38393 increases GDNF production in a foetal human
astrocyte cell line (Kinor et al., 2001). In addition, dopamine
increases GDNF secretion in rodent primary astrocyte cultures
(McNaught and Jenner, 2000).
Trophic actions promoted by dopamine agonists appear to be
brain region-specific.While cultured foetal striatal cells respond to
apomorphine treatment by increasing BDNF and GDNF, hippo-
campal cells are unable to respond (Guo et al., 2002). Conditioned
medium from substantia nigra astroglial cultures treated with D3
agonists show remarkably increased levels of GDNF and BDNF,
while no changes are observed in medium from striatal or cortical
astroglia (Du et al., 2005). Moreover, D2R/mice show a 40–50%
reduction of GDNF mRNA in the major target areas of substantia
nigra/VTA dopaminergic neurons, whereas GDNF mRNA levels are
unaltered in other brain areas receiving dopaminergic innervation
(Bozzi and Borrelli, 1999). Conversely, the knockout mice present
changes in the expression of neurotrophin-4 (NT-4) in other brain
areas. There are no changes in the NT-4 mRNA levels in the
substantia nigra but the levels in the parietal cortex, an area
receiving innervation from the VTA, are substantially reduced
(Bozzi and Borrelli, 1999). Collectively, these findings support the
idea that dopamine regulates the expression of GDNF and other
neurotrophic factors. Therefore, depletion of dopamine upon
nigrostriatal injury would lead to a decrease in GDNF expression,
unless other factors related to the response to neuronal injury
modulate GDNF expression. Among them might be pro-inflam-
matory molecules, as discussed later.
Fig. 1. Regulation of GDNF expression in the nigrostriatal system in the healthy adult brain and upon injury. Dopaminergic neurons projecting from the substantia nigra pars
compacta (SN) to the striatum (Str) are shown in yellow in a scheme of the rat brain (upper left corner). In the healthy brain, dopamine (DA) released from active neurons is
likely to stimulate the expression of GDNF by target neurons in the striatum, and by astrocytes as well (supporting data detailed in Section 4). In turn, GDNF is taken by
dopaminergic terminals and retrogradelly transported to the cell body in the substantia nigra. A small tonic production of GDNF by astrocytes is likely to occur in the normal
adult brain, regulated by cell–cell contact and soluble signals. Neuronal injury triggers astrogliosis and activation of microglial cells. GDNF expression by astrocytes is greatly
enhanced upon neuronal damage, andGDNF receptorswere shown to be up-regulated in the substantia nigra upon damage to the nigrostriatal pathway (detailed in Section 5).
Interleukin-1b (IL-1b), and other, still unidentified, soluble factors mediate GDNF up-regulation upon dopaminergic injury.
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the afferent activity is lost. In this situation, dopamine receptor
agonists, mimicking endogenous dopamine, promote neuropro-
tection through an increase in GDNF expression. Dopamine
receptor agonists protect mouse striatal neurons against 6-
hydroxydopamine (6-OHDA) toxicity (Iida et al., 1999), and
neuroblastoma SH-SY5Y cells and mesencephalic cultures from
the toxicity of 1-methyl-4-phenylpyridinium (MPP+), the active
metabolite of MPTP (Presgraves et al., 2004). D2 agonists are also
effective against the excitotoxicity evoked by glutamate agonists in
mesencephalic neurons (Sawada et al., 1998b). Although other
mechanisms have been proposed, such as the induction of
antioxidant defences (Iida et al., 1999), the neuroprotection
afforded by dopamine or dopamine receptor agonists has been
associated with their ability to promote the expression of severalneurotrophic factors. In fact, D3 receptor preferring agonists
protectmesencephalic neurons against aMPP+ lesion by increasing
the secretion of both GDNF and BDNF (Du et al., 2005).
Serotonin (5-HT) is another monoamine shown to promote
GDNF mRNA expression in rat C6 glioma cells. This increase
involves transactivation of FGF receptors via 5-HT2 receptor
(Tsuchioka et al., 2008).
Recent data show that adenosine is also able to promote GDNF
transcription and increase GDNF release in primary cultures of rat
astrocytes, through the activation of A2B receptors (Yamagata et al.,
2007). The adenosine-induced increase in the expression of
neuroprotective molecules such as NGF (Ciccarelli et al., 1999)
and GDNF probably represents a neuroprotective response since
adenosine levels increase dramatically upon injury (Parkinson
et al., 2002).
A. Saavedra et al. / Progress in Neurobiology 86 (2008) 186–215192In addition to dopamine, serotonin, or adenosine, other
neurotransmitters control GDNF expression. Sub-seizure doses
of the glutamate receptor agonists N-methyl-D-aspartate (NMDA)
or kainate increase GDNF mRNA levels in the adult rat striatum,
and similar findings come from striatal astrocyte cultures (Ho et al.,
1995).Moreover, glutamate induces the expression of GDNFmRNA
and the release of GDNF protein in a concentration-dependent
manner in cultured rat astrocytes (Yamagata et al., 2002).
Altogether, these results indicate that activation of glutamate
receptors is able to modulate GDNF expression and suggest a role
for GDNF in neuronal plasticity.
Furthermore, at excitotoxic concentrations, glutamate or
glutamate receptor agonists might bring on the contribution of
reactive astrocytes to the increase in GDNF expression. GDNF
mRNA increases in the striatum of rats after pilocarpine-induced
seizures (Schmidt-Kastner et al., 1994), whereas other studies
show that GDNF mRNA is up-regulated in the hippocampus
following kainate-induced seizures (Humpel et al., 1994; Trupp
et al., 1997). ThemRNA levels of GDNF receptors Ret andGFRa1 are
also up-regulated in the hippocampus following kainate-induced
seizures (Trupp et al., 1997; Reeben et al., 1998). In addition, an
enhancement of GDNF mRNA in reactive astrocytes occurs upon
administration of excitatory amino acids to the striatum (Bresjanac
and Antauer, 2000; Marco et al., 2002), and these changes in GDNF
mRNA levels can reflect an endogenous trophic response of striatal
cells to the excitotoxic insult. In sum, these observations support a
role for the activation of glutamate receptors in GDNF expression
in response to excitotoxic injury.
5. GDNF expression upon nigrostriatal injury: role of neuron-
glia cross-talk
Nervous tissue responds to injury up-regulating protective and
repairing mechanisms (reviewed by Benn and Woolf, 2004).
Damaged neurons change their own gene expression and stimulate
nearby astrocytes and microglial cells to provide support. In the
intact adult brain, GDNF expression is largely neuronal, as
astroglial cells were not found to express detectable GDNF (Blum
and Weickert, 1995; Pochon et al., 1997; Bizon et al., 1999;
Bresjanac and Antauer, 2000). Upon injury, glial cells appear to
become the predominant source of trophic substances. It should be
noted that, besides GDNF (Bresjanac and Antauer, 2000; Nakagawa
and Schwartz, 2004; Chen et al., 2006a), other trophic factors are
up-regulated in the injured nigrostriatal system, namely, BDNF,
FGF and NGF (Nakajima et al., 2001; Yurek and Fletcher-Turner,
2002; Nakagawa et al., 2005; Chen et al., 2006a). The neuronal
expression of trophic factors associated with injury is a rapid and
transient activity-dependent expression, whereas a delayed and
more persistent injury-induced expression occurs in glial cells
(Hughes et al., 1999).
The selective damage of nigrostriatal dopaminergic neurons in
animalmodels of PD altersmRNA and/or GDNF protein levels, both
in the striatum and in the substantia nigra (Fig. 1), although some
contradictory findings exist. In the striatum, an increase in GDNF
mRNA or protein levels has been observed after 6-OHDA-induced
(Zhou et al., 2000; Nakajima et al., 2001; Yurek and Fletcher-
Turner, 2001, 2002; Hida et al., 2003) or MPTP-induced injury
(Tang et al., 1998). However, other authors have failed to detect
changes in striatal GDNF levels after 6-OHDA lesion (Stromberg
et al., 1993; Smith et al., 2003; Anastasia et al., 2007) or MPTP
treatment (Inoue et al., 1999; Collier et al., 2005). These conflicting
results might arise from differences in the injury models and
protocols, or different time points analysed. In general, GDNF
protein levels increase in the first 2–3 weeks after the 6-OHDA
lesion and decrease thereafter, such that at 6 or 12 weeks, no up-regulation is detected, or decreased levels are observed (Nakajima
et al., 2001; Yurek and Fletcher-Turner, 2002). Moreover, the
neurotrophic response to injury depends on the age of the animals.
In general, young animals show a greater capacity to up-regulate
neurotrophic factors (Yurek and Fletcher-Turner, 2001; Collier
et al., 2005).
Fewer studies focus on nigral GDNF expression after nigros-
triatal lesions, yielding also conflicting results. Some studies found
no changes in GDNF expression upon MPTP-induced (Inoue et al.,
1999) or 6-OHDA-induced injury (Yurek and Fletcher-Turner,
2001). Later on, the same authors reported a transient increase in
GDNF levels in the midbrain 3 days after lesion, whereas at 12
weeks a down-regulation was observed (Yurek and Fletcher-
Turner, 2002). Decreased nigral GDNF protein levels were also
reported 2 weeks after a 6-OHDA lesion (Anastasia et al., 2007).
Gene expression profiles, obtained with cDNA microarrays, show
GDNF up-regulation in the substantia nigra and striatum after
MPTP intoxication (Grunblatt et al., 2001a; Mandel et al., 2002),
and in striatal astrocytes from 6-OHDA lesioned rats (Nakagawa
and Schwartz, 2004). We have shown that mild damage to
dopaminergic neurons in neuron-glia cultures from substantia
nigra, but not extensive damage, induces GDNF up-regulation in
astrocytes (Saavedra et al., 2006). Since GDNF up-regulation is not
observed in cultures previously treated with 6-OHDA, we propose
that GDNF induction in astrocytes requires signalling from injured
dopaminergic neurons that are still capable of signalling (Saavedra
et al., 2006).
It is unknown whether the endogenous production of GDNF
might be effective in protecting nigrostriatal dopaminergic
neurons, and contribute to the very slow progression of PD. It
should be noted that the data showing dopaminergic protection
and repair in animal models of PD involved the delivery of
exogenous GDNF, encapsulated GDNF producing cells, or the
transduction of viral-encoded GDNF (e.g. Bilang-Bleuel et al., 1997;
Gash et al., 2005; Sajadi et al., 2006).
It was proposed that changes in the levels of neurotrophic
factors, due to alterations in the synthesis, release or activity,
associated with ageing or genetic factors, might be involved in the
neuronal loss observed in neurodegenerative diseases as PD
(reviewed by Siegel and Chauhan, 2000; Mattson and Magnus,
2006). Post-mortem studies investigating GDNF distribution in the
human parkinsonian brain have yielded conflicting results. In situ
hybridization studies failed to detect GDNF mRNA in the human
midbrain (Hunot et al., 1996), and no significant differences were
found in GDNF content in the caudate-putamen and substantia
nigra between PD and control samples (Mogi et al., 2001). Since the
levels of other growth factors are decreased in PD brains, it was
suggested that the unchanged levels of GDNF in PDmight be due to
compensatory production by glial cells (Mogi et al., 2001).
However, using immunohistochemistry, large reductions in GDNF
content are reported in surviving PD substantia nigra neurons
(Chauhan et al., 2001). More recently, using real-time PCR, modest
but significantly increased levels of a GDNF isoform were found in
the putamen of PD patients with marked nigral neuronal loss
(Backman et al., 2006). Whatever might be the endogenous
changes of neurotrophic factors in PD, a therapy with GDNF might
prevent the progression of the disease and restore function (Gill
et al., 2003; Slevin et al., 2005).
Astrocytes are key elements in the brain response to injury.
Activated astrocytes up-regulate antioxidant molecules, mem-
brane transporters, and trophic factors that support neuronal and
glial survival, and tissue repair (reviewed by Liberto et al., 2004).
Recent reports suggest that astrocytes can be important targets for
the development of neuroprotective drugs (Chen et al., 2005b;
Darlington, 2005). Supporting this view, most of the works
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performed in astrocyte or glial cell line cultures and fewer studies
used mesencephalic (Guo et al., 2001, 2002; Nitta et al., 2004) or
hippocampal neuronal cultures (Lenhard et al., 2002; Nitta et al.,
2004; Cen et al., 2006). Furthermore, as discussed later, astrocytic
GDNF production has been proposed to explain the neuroprotec-
tive/therapeutic effects of several compounds, including apomor-
phine, selegiline, riluzole, anti-depressants, melatonin, or vitamin
D3.
Microglia, the resident immune cells of the brain, proliferate
and become immunocompetent, with the ability to secrete a
number of cytotoxic and trophicmolecules (reviewed by Block and
Hong, 2005). Up-regulation of GDNF by astrocytes or microglial
cells occurs in several injury models (Liberatore et al., 1997;
Batchelor et al., 1999; Bresjanac and Antauer, 2000; Satake et al.,
2000; Wei et al., 2000; Miyazaki et al., 2001; Ikeda et al., 2002;
Marco et al., 2002; Hashimoto et al., 2005a). This switch in the
production of GDNF from neurons to glial cells may provide a local
mechanism to limit neuronal loss and promote regeneration.
Therefore, it is important to understand the cross-talk among
neurons, astrocytes, and microglia leading to glial GDNF expres-
sion after injury.
Although a great deal of evidence indicates that nigrostriatal
injury may induce GDNF expression in both astrocytes and
microglial cells, it is not completely understood how damaged
neurons signal glia. Moreover, it is unclear whether similar or
differentmechanisms control GDNF expression in the striatum and
in the substantia nigra, in physiological conditions and after injury.
The intercellular signals involved in the communication between
damaged neurons and glial cells are potential therapeutic targets
aimed at up-regulating the endogenous expression of neurotrophic
factors.
5.1. Inflammatory signals and GDNF expression
Pro-inflammatory molecules are among the candidate signals
involved in the intercellular talk that induces glial GDNF
expression after injury. Indeed, elevated GDNF expression is
observed in response to lipopolysaccharide (LPS) and to the pro-
inflammatory cytokines IL-1b, IL-6, tumor necrosis factor (TNF)-a
and TNF-b in C6 cells (Appel et al., 1997; Verity et al., 1998) and in
U-87MG glioblastoma cells (Verity et al., 1999). In cultured
astrocytes both exogenous TNF-a, via TNF receptors, and
endogenously produced TNF-a induce GDNF expression, suggest-
ing that an autocrine loop contributes to the production of
neurotrophic factors in response to inflammation (Kuno et al.,
2006). LPS also increases GDNF mRNA expression in rodent
primary astrocyte cultures (Remy et al., 2003; Kuno et al., 2006) as
well as GDNF secretion (McNaught and Jenner, 2000). However,
both LPS and TNF-a trigger a significant decrease in the mRNA
level of GFRa1 (Remy et al., 2003). In vivo, a high dose of LPS
improves locomotor function after spinal cord injury in rats greater
than a lowdose, which is consistentwith the expression of GDNF in
microglia/macrophages (Hashimoto et al., 2005c). These results are
in accordance with LPS-induced GDNF mRNA expression in
microglial cultures (Tanaka et al., 2008). This suggests that repair
of CNS injuries can occur through GDNF produced by activated
microglia/macrophages. The stimulatory effect of TNF-a, TNF-b,
IL-1b and LPS seems to be restricted to glial cells since SK-N-AS
neuroblastoma cells respond to these pro-inflammatory agents
repressing GDNF release (Verity et al., 1999).
Having in mind evidences that the transcription factor nuclear
factor-kB (NF-kB) can regulate GDNF expression (Woodbury et al.,
1998; Baecker et al., 1999; Tanaka et al., 2000), the effect of pro-
inflammatory agents on GDNF expression is in agreement with thefact that IL-1b, TNF-a, andLPSactivateNF-kB (Moynaghetal., 1993;
Xie et al., 1994; Diehl et al., 1995). Moreover, NF-kB-DNA binding
increases in U-87MG glioblastoma cells upon IL-1b treatment
whereas dexamethasone significantly represses GDNF release
(Verity et al., 1999). Furthermore, the putative NF-kB binding site
of the GDNF gene effectively binds nuclear protein in the mouse
astroglial cell line TGA-3 after IL-1b treatment (Tanaka et al., 2000).
Taken together, these results suggest that NF-kB activation is
responsible for increased GDNF expression in response to IL-1b. In
contrast, results from microglia cultures show that LPS-induced
GDNF expression is a Jun N-terminal kinase (JNK)-dependent but
NF-kB-independent phemonenon (Tanaka et al., 2008).
Conflict might arise when comparing the positive impact of IL-
1b on GDNF levels in glial cell lines (Appel et al., 1997; Verity et al.,
1998, 1999), or in mouse astrocyte cell cultures prepared from
neonatal cortices (Appel et al., 1997), with the lack of effect of IL-1b
on GDNF expression in striatal astrocyte cultures or when injected
intrastriatally in mice (Ho and Blum, 1997). In line with this, data
from our group indicates that IL-1b is not involved in GDNF up-
regulation in striatal cultures exposed to conditioned medium
from H2O2- or L-DOPA-challenged substantia nigra neuron-glia
cultures (unpublished results), whereas we have shown that IL-1b
mediates GDNF up-regulation in substantia nigra cell cultures in
response to H2O2 or L-DOPA (Saavedra et al., 2007). Altogether, the
data suggests that regulation of GDNF expression can be different
in different cell types and/or brain regions (Fig. 1).
In summary, there is evidence that inflammatory stimuli induce
GDNF expression in astrocytes. The rapid appearance of cytokines
after injury suggests that TNF-a and IL-1b may in part regulate
injury-induced glial GDNF synthesis/release, providing neuro-
trophic support to GDNF-responsive neurons under inflammatory
conditions in the CNS.
Considering signal molecules that can stimulate astrocytic
GDNF production after injury, we should also mention endothelins
(ETs). Brain ETs were proposed to be involved in responses to
injury since altered expression of ETs in reactive astrocytes is
observed in many pathological conditions (reviewed by Schinelli,
2006). ETs are suggested to play a role in functional changes in
astrocytes after brain injury because activation of their ET
receptors stimulates several astrocytic pathophysiological
responses leading to ‘reactive astrocytes’ such as hypertrophy,
proliferation, and production of neurotrophic substances (refer to
Koyama et al., 2003a,b for references). A proteomic analysis also
found that ET-1 induces changes of proteins involved in
cytoskeletal reorganization, cell adhesion, signal transduction,
and differentiation during reactive gliosis (Egnaczyk et al., 2003).
Treatment of rat cultured astrocytes with ET-1 increases GDNF
mRNA levels and stimulates the release of GDNF (Koyama et al.,
2003a). This occurs via ETB receptors since the effect is inhibited by
an ETB receptor antagonist but not by an ETA receptor antagonist.
Similar observations were done in vivo since intracerebroventri-
cular (icv) administration of Ala1,3,11,15-ET-1, an ETB receptor
agonist, for 7 days increases GDNF mRNA in the rat hippocampus
while increasing BDNF level in the striatum (Koyama et al., 2003b).
The Ala1,3,11,15-ET-1-induced increases in GDNF and BDNF mRNA
levels are accompanied by increases in immunoreactive GDNF and
BDNF. Increases in glial fibrillary acid protein- and vimentin-
positive astrocytes are also observed in the same regions, but no
neurodegeneration or activation of microglia/macrophages are
registered suggesting that Ala1,3,11,15-ET-1 can activate astrocytes
by itself. In cultured rat astrocytes, Ala1,3,11,15-ET-1 also increases
GDNF as well as BDNF mRNA levels (Koyama et al., 2003b). These
results suggest that activation of brain ETB receptors induces
reactive astrocytes and triggers GDNF and BDNF expression.
Therefore, the finding that ET-1/ETB activation increases GDNF
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after brain injury.
6. A healthy life style and GDNF expression
6.1. Caloric restriction: less food, more GDNF?
It is well documented that caloric restriction and reduced meal
frequency/intermittent fasting can protect against diabetes,
cardiovascular disease and cancer, and increase life span in
rodents. Although less is known about the influence of meal size
and frequency on neurological disorders, some studies show that
caloric restriction and intermittent fasting diets are neuroprotec-
tive and improve functional outcome in animal models of stroke,
Parkinson’s and Huntington’s disease (reviewed by Mattson,
2005). Moreover, data from epidemiological studies suggest that
individuals with low-calorie, low-fat diets may have reduced risk
of PD (Logroscino et al., 1996).
The mechanisms involved in the beneficial effects of caloric
restriction and reduced meal frequency/intermittent fasting on
health and disease susceptibility are being uncovered. They are
thought to be linked with beneficial responses to mild cellular
stress. Those dietarymanipulationsmay prolong the health span of
the nervous system by acting upon important metabolic and
cellular signalling pathways to stimulate the production of protein
chaperones, antioxidant enzymes, and neurotrophic factors that
help cells to deal with stress and resist disease (Martin et al., 2006).
Focusing on the role played by neurotrophic factors on the
positive effect of caloric restriction and reduced meal frequency/
intermittent fasting, most studies have implicated BDNF (reviewed
by Mattson, 2005). However, GDNF may also be coming into play.
Dietary restriction in adult mice protects against the dysfunction
and degeneration of nigrostriatal dopaminergic neurons induced by
MPTP, and deficits in motor function decrease markedly in those
animals (Duan and Mattson, 1999). When a non-metabolizable
analogue of glucose (2-deoxy-D-glucose) is administered ad libitum
to mice to mimic dietary restriction, a reduction of damage to
dopaminergic neurons in the substantia nigra and improved
behavioural outcome following MPTP treatment are observed.
Moreover, treatment with 2-deoxy-D-glucose protects cultured
dopaminergic cells against oxidative andmetabolic insults relevant
to the pathogenesis of PD (Duan and Mattson, 1999). Although this
study did not address GDNF levels, more recent observations raise
the hypothesis that increased GDNF levels upon dietary restriction
might also contribute to the protection of dopaminergic neurons
observed in this model. This hypothesis arises from recent
observations. A low-calorie diet reduces the loss of dopaminergic
neurons from the substantia nigra, the severity of neurochemical
deficits, andmotordysfunction inanon-humanprimatemodelofPD
(Maswood et al., 2004). Furthermore, monkeys maintained for 6
months on a 30% caloric restriction diet exhibit significantly higher
levels of GDNF in the caudate nucleus compared with control
monkeys, suggesting that the protective effect of reduced calorie
diet may result from up-regulation of GDNF expression and
consequent activation of neuroprotective signal transduction path-
ways in dopaminergic neurons (Maswood et al., 2004). Since a
caloric restriction diet increases the amount of endogenousGDNF in
the brain of monkeys, it suggests that it may be possible to
ameliorate PD, at least partially, through dietary manipulations. It
should also be stressed that, likely due to, and consistent with the
observation that caloric restriction attenuates MPTP-induced
depletion of dopamine, the distancemoved and speed ofmovement
increasedmore than 2-fold in caloric restricted monkeys compared
with those on control diet (Maswood et al., 2004). Based on an
evolutionary perspective, and on experimental data, it wasspeculated that the neuroprotective effects of caloric restriction
could be due to the induction of growth factors by increased motor
activity (Finch, 2004). In fact, activation of the same cellular and
molecular pathways that occur in response to mild dietary
restriction and intermittent fasting-induced stress can occur in
response to physical exercise and cognitive stimulation (Mattson
et al., 2004). Therefore, the impact of physical exercise and cognitive
stimulation on GDNF expression will be discussed next.
6.2. Physical exercise and GDNF expression in the nigrostriatal system
Among environmental factors that up-regulate the expression
of GDNF, and might therefore protect against PD, are physical
exercise and environmental enrichment. In fact, enriched envir-
onmental conditions and increased physical activity are neuro-
protective in models of nigrostriatal system injury (Bezard et al.,
2003b; Faherty et al., 2005; Steiner et al., 2006; Jadavji et al., 2006;
Yoon et al., 2007).
Physical exercise increases the expression of GDNF in the
nigrostriatal system (Cohen et al., 2003; Faherty et al., 2005).
Unilateral cast of a limb in rats, which forces the animal to rely on
the use of the contralateral limb, significantly increased GDNF
protein levels in the striatum contralateral to the overused limb,
but not in the ipsilateral striatum (Cohen et al., 2003), suggesting
that striatal activity up-regulates GDNF. The increase in GDNF
levels was transient, reaching a maximum at 3 days after casting,
and returning to normal levels despite continued forced limb use.
Exercise-induced expression of GDNF was correlated with the
protection of dopaminergic neurons against MPTP toxicity
(Faherty et al., 2005), and the prevention of motor impairment
due to a 6-OHDA lesion (Cohen et al., 2003). Sparing of
dopaminergic neurons from toxin action, assessed by measuring
dopamine, its metabolites and transporters in the striatum, or TH-
positive cells in the substantia nigra, strongly supports a
neuroprotective role for physical exercise. These studies raised
the hypothesis (Smith and Zigmond, 2003) that up-regulation of
GDNFmightmediate, or at least contribute to, the protection of the
nigrostriatal pathway, and the improvement of motor function
observed in many studies of forced limb use or running-wheel
exercise in both the 6-OHDA (Mabandla et al., 2004; Tillerson et al.,
2001, 2003) and theMPTP (Fisher et al., 2004; Tillerson et al., 2003)
models of PD. However, exercise of the affected limb is protective
only when initiated in a time window after toxic injury. Complete
behavioural and neurochemical sparing is achieved when exercise
of the affected limb begins immediately after the lesion, whereas
no sparing occurswhen exercise begins 7 days after 6-OHDA lesion
(Tillerson et al., 2001). Furthermore, the data from animal models
might parallel observations of beneficial effects of exercise on
motor and non-motor symptoms in PD patients (Lehman et al.,
2005; reviewed by Gage and Storey, 2004; Logroscino et al., 2006).
In addition, epidemiological studies show a negative correlation
between the regular practice of exercise and the prevalence of PD
in humans, at least in males (Tsai et al., 2002; Chen et al., 2005a).
Thus, exercise might constitute a neuroprotective therapy for PD
contributing to slow the progressive degeneration of dopaminergic
neurons. However, few studies examined GDNF expression upon
exercise in healthy animals (Cohen et al., 2003; Faherty et al.,
2005), and only one reports the effect of exercise on GDNF
expression in lesioned animals that might underlie sparing of
dopaminergic neurons, sprouting and regeneration of the remain-
ing terminals, and improved behaviour (Faherty et al., 2005).
Animalsexercisedontherunning-wheelpriororafteraunilateral
striatal 6-OHDA lesion, showed a fastermotor recovery compared to
non-exercised animals. However, exercise had no significant effects
on the density of striatal dopamine transporters or on the number of
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authors argued that the exercise-induced enhancement of motor
recovery in PDmodelsmight not be a consequence of the protection
or rescue of dopaminergic neurons. It was proposed that exercise-
induced facilitation of motor recovery may occur due to increased
dopaminergic transmission at dopaminergic synapses, or to
adaptations at other sites within the basal ganglia circuitry (O’Dell
et al., 2007) that occur upon changes in dopaminergic synapses
(Bezard et al., 2003a). Nevertheless, the report by O’Dell et al. is
compatible with the idea that exercise protects dopaminergic
neurons from injury. While most studies were carried out with
lesions causing an extensive dopaminergic lost (Cohen et al., 2003;
Faherty et al., 2005; Tillerson et al., 2001, 2003), O’Dell et al. (2007)
used low doses of 6-OHDA to induce a small graded lesion of
dopaminergic terminals aimed at mimicking the progressive
degeneration at the onset of PD symptoms in patients. In their
model, spontaneousrecoveryoccurredafterthe6-OHDAlesion,even
in the non-exercised animals, but exercise in the running-wheel
markedly accelerated the process.
On the other hand, the increase in dopaminergic transmission,
proposed to underlie the exercise-induced facilitation of motor
behaviour, might also involve GDNF. GDNF was shown to enhance
dopamine biosynthesis due to phosphorylation and increased
activity of TH (Kobori et al., 2004; Salvatore et al., 2004), and
increased activation of the enzyme producing BH4 (5,6,7,8-
tetrahydrobiopterin), a cofactor for TH (Bauer et al., 2002). This
enhancement of dopamine synthesis likely leads to an increase in
quantal release as observed in postnatal dopaminergic neurons in
culture (Pothos et al., 1998). Furthermore, GDNF increases
dopamine release owing to the enhancement of the excitability
of midbrain dopaminergic neurons, which is associated with the
inhibition of A-type K+ channels (Yang et al., 2001), and potentiates
the activation of Ca2+ channels and excitatory transmission in
midbrain neurons (Wang et al., 2003).
The neuroprotective effects of exercise on the nigrostriatal
system might also be due to other neurotrophic factors, which are
known to be up-regulated by exercise and to ameliorate damage in
other brain areas, as BDNF and FGF-2 in the hippocampus (Neeper
et al., 1995; Gomez-Pinilla et al., 1997; Cotman and Berchtold,
2002). In addition, peripheral factors increased by exercise and
capable of crossing the blood–brain barrier, like insulin growth
factor-1 (Carro and Torres-Aleman, 2006) or Ca2+ (Sutoo and
Akiyama, 2003), might contribute to exercise-induced neuropro-
tection and/or function improvement. For instance, increases in
brain Ca2+, subsequent to the peripheral increase due to exercise,
increase dopamine levels in the striatum (Sutoo and Akiyama,
2003). In addition, exercise increases anti-inflammatorymolecules
in the plasma that might alleviate conditions contributing to
dopaminergic damage (Cadet et al., 2003).
In conclusion, although the beneficial effects of exercise on the
preservation or recovery of nigrostriatal-dependent motor func-
tions are unquestionable, both in animal models and in PD
patients, the mechanisms and the neuronal circuitry involved are
not yet completely understood. How does exercise increases GDNF
expression? This issue was not addressed directly. However, since
GDNF production is activity dependent, dopamine is known to
stimulate GDNF expression, and exercise was shown to increase
dopamine in the striatum (Sutoo and Akiyama, 2003), one may
envisage that increased dopamine receptor binding during activity
of striatal circuitry may mediate GDNF expression.
6.3. Environmental enrichment and GDNF expression
Environmental enrichment (a combination of increased social
interaction, learning, and exercise) increases GDNF mRNA in thesubstantia nigra and in the striatum and totally protects against
MPTP-induced parkinsonism (Faherty et al., 2005). Moreover,
adult mice raised in an enriched environment for only 2 months
are significantly more resistant to MPTP compared with mice
raised in a standard environment since they show only a 40%
dopaminergic cell loss after MPTP treatment, in contrast to the 75%
loss observed in mice raised in a standard environment (Bezard
et al., 2003b). In addition, enriched environment increases the
expression of BDNF in the striatum (Bezard et al., 2003b), but the
effect of enriched environment on the levels of GDNF was not
addressed in this study. Previously, an enriched environment was
shown to induce the expression of GDNF and to increase the
phosphorylation of the transcription factor cAMP response
element binding protein (CREB), while reducing the spontaneous
apoptosis in the rat hippocampus by 45%, and protecting against
kainate-induced seizures and excitotoxic injury (Young et al.,
1999). These results support that a stimulating environment has a
positive impact on brain health, and are consistent with clinical
evidence showing an association between higher educational
accomplishment and reduced risk of PD-related dementia (Glatt
et al., 1996).
Growing evidence show the possibility of reducing the risk for
age-related neurodegenerative disorders through dietary and
behavioural changes inducing neuronal plasticity and survival.
One can conclude that dietary manipulations, physical exercise
and cognitive stimulation, which might induce GDNF up-regula-
tion, represent novel drug-free approaches for disease prevention
and treatment.
7. Pharmacological agents to boost GDNF expression
It is interesting to notice thatmany pharmacological agents that
have proven useful in the symptomatic treatment of PD are
increasingly recognized as modulators of GDNF expression, as well
of other neurotrophic factors, raising the possibility that their
beneficial effects are also mediated by the induction of trophic
factors and subsequent protection/rescuing of dopaminergic
neurons. In this section, we will focus on the effect on GDNF
expression of drugs already used or with potential interest to treat
PD and other neurodegenerative diseases or neurological dis-
orders.
7.1. Agents that increase dopaminergic transmission
As mentioned in Section 4, dopaminergic activity is able to
promote GDNF expression. Since the main characteristic of PD is
the striatal dopamine deficit, most therapeutic approaches involve
the stimulation of dopaminergic transmission, either by using the
dopamine precursor L-DOPA, dopamine receptor agonists, or
dopamine uptake and dopamine metabolism inhibitors (Fig. 2).
Therefore, it is not surprising that these agents induce GDNF
expression in the nigrostriatal system.
7.1.1. Dopamine agonists
Several dopamine agonists are used in themanagement of PD as
replacement for the endogenous dopamine. Apomorphine, a D1/D2
dopamine receptor agonist, is currently used as an anti-parkinso-
nian drug (reviewed by Subramony, 2006). Administration of
apomorphine to patients reduces the need for other anti-
parkinsonian medication, induces a significant reduction in
dyskinesias and a marked improvement in the quality of life
(Manson et al., 2001). Besides the increase in dopaminergic
transmission, the beneficial effects of this agonist on PD patients
might involve neuroprotection through a wide range of mechan-
isms in addition to its antioxidant actions (reviewed by Kyriazis,
Fig. 2. Schematic overview of pathways leading to an increase in dopaminergic transmission and their regulation by agents known to increase GDNF expression.
A. Saavedra et al. / Progress in Neurobiology 86 (2008) 186–2151962003). Apomorphine up-regulates the expression of several
neurotrophic factors, including GDNF. It increases GDNF mRNA
levels and the amount of GDNF protein in the culturemedium from
mouse astrocytes (Ohta et al., 2000; Shimazu et al., 2003a) and
mesencephalic cells (Guo et al., 2002). Furthermore, apomorphine
stimulates the synthesis and release of GDNF and BDNF in striatal
cultures, and effectively prevents dopaminergic neuron loss in vitro
(Guo et al., 2002). These neurotrophic effects might contribute to
the reported effects of apomorphine against MPTP-induced striatal
dopaminergic neurodegeneration in mice (Grunblatt et al., 2001b)
and provide another potential mechanism for the anti-parkinso-
nian action of this drug in PD patients.
Besides the increase in GDNF and BDNF levels, treatment with
apomorphine also increases FGF-2 expression in striatal astrocytes,
both at the mRNA and protein level, an effect correlated with the
activation of D1 and D2 receptors (Li et al., 2006a). FGF-2 exerts a
potent neuroprotective action on nigral dopaminergic neurons in
the MPTP mouse model of PD (Otto and Unsicker, 1990, 1993;
Chadi et al., 1993). FGF-2 also increases dopaminergic graft
survival and function in a rat model of PD (Takayama et al., 1995).
Moreover, fibroblasts genetically engineered to produce FGF-2 and
implanted into the striatum attenuate the damage caused by
intrastriatal injection of 6-OHDA (Shults et al., 2000). More
recently, FGF-2 was reported to protect against rotenone-induced
cell death in both SH-SY5Y cells and cultured dopaminergic
neurons (Hsuan et al., 2006).
The neuroprotective properties of FGF-2 might be related, at
least partially, to the effect of FGF-2 on GDNF expression. Indeed,
FGF family members increase GDNF mRNA expression and release
in C6 glioma cells (Suter-Crazzolara and Unsicker, 1996; Verityet al., 1998) and in U-87MG glioblastoma cells (Verity et al., 1999).
In addition, FGF-2 up-regulates GDNF and GFRa1 expression in
hippocampal neurons (Lenhard et al., 2002). FGF-2 enhances the
activity of the GDNF promoter (Grimm et al., 1998). The
enhancement of GDNF expression by FGF-2 can occur through a
consensus cAMP response element (CRE) sequence present within
the GDNF promoter (Woodbury et al., 1998; Baecker et al., 1999)
since FGF-dependent gene activation requires CRE-2 (Tan et al.,
1994), and FGF activates a CREB kinase (Tan et al., 1996).
Another dopamine agonist, cabergoline (a D2/weak D1 agonist),
has been used as adjunctive therapy with L-DOPA and as de novo
treatment for PD patients. Repeated administration of cabergoline
to mice attenuates both 6-OHDA-induced nigrostriatal dopami-
nergic dysfunction and dopaminergic cell death (Yoshioka et al.,
2002). The neuroprotection provided by cabergoline relies on the
activation of the glutathione system in vivo and scavenging of free
radicals in vitro (Yoshida et al., 2002). More recently, another
mechanism possibly contributing to the neuroprotective action of
cabergoline has been added to the list: cabergoline potently
stimulates GDNF synthesis and secretion in primary cultures of
mouse astrocytes (Ohta et al., 2004). Cabergoline-induced GDNF
increases are significantly blocked by the selective dopamine D2
antagonist sulpiride (Ohta et al., 2004) indicating the involvement
of dopamine receptors.
The D3-preferring receptor agonists pramipexole and ropinirole,
widely used in clinical practice to treat PD patients, also show
putative neurotrophic propertieswith promising retardation effects
on disease progression (Clarke andGuttman, 2002; Parkinson Study
Group, 2002b; Barone, 2003; Whone et al., 2003). Pramipexole
and ropinirole possess neuroprotective properties, both in vitro
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2000; Parkinson Study Group, 2002b). Incubation of mesencephalic
cultures with pramipexole and ropinirole, or with conditioned
medium from pramipexole- and ropinirole-treated mesencephalic
cultures or substantia nigra astroglia increases the number of
dopaminergicneurons inculture (Duetal., 2005). The levelsofGDNF
and BDNF in the conditioned medium of mesencephalic cultures
treated with the D3 dopamine receptor agonists are significantly
increased. The observation that GDNF and BDNF neutralizing
antibodies greatly reduce the neurotrophic effects of pramipexole
and ropinirole (Duetal., 2005) suggest that thesedopamine receptor
agonists exert neurotrophic effects on cultured dopaminergic
neurons by modulating the production of endogenous GDNF and
BDNF.
In conclusion, the effects of dopamine receptor agonists both in
cell cultures and in animal models of PD show that dopamine
receptors present in neurons and astrocytes might control GDNF
expression. These receptors may ensure the activity-dependent
expression of GDNF and fulfil a maintenance role in dopaminergic
circuits.
7.1.2. L-DOPA
L-DOPA remains the drug of choice in the symptomatic
treatment of PD, and GDNF has proven to be a potent factor for
the protection of nigral dopaminergic neurons against toxin-
induced degeneration in vivo. However, in contrast to the effect of
dopamine agonists on GDNF expression, the effect of L-DOPA on
GDNF levels in the nigrostriatal system has not been extensively
addressed. Many in vitro studies showed toxic effects of L-DOPA on
midbrain dopaminergic neurons but its toxicity has not been
proven in vivo (reviewed by Olanow et al., 2004). In fact, trophic
effects of L-DOPA were observed on dopaminergic neurons
cocultured with astrocytes (Mena et al., 1997) but, to our
knowledge, our group is the only describing the effect of L-DOPA
on GDNF levels in the nigrostriatal system. We have shown that L-
DOPA induces GDNF up-regulation at the mRNA and protein levels
in substantia nigra neuron-glia cell cultures, in a process involving
soluble mediators that signal astrocytes to increase GDNF
expression (Saavedra et al., 2006). We have also addressed the
effect of L-DOPA treatment on GDNF levels in the 6-OHDA rat
model of PD. Our preliminary data indicate that L-DOPA increases
GDNF levels in the striatum (1-day treatment) and in the substantia
nigra (5-day treatment) of 6-OHDA-lesioned animals (unpublished
results). Results from the recent ELLDOPA clinical trial support the
concept that L-DOPA may slow down the progression of PD (Fahn,
2005). It is therefore tempting to relate this neuroprotective effect
with our observation that L-DOPA increases GDNF levels.
7.1.3. MAO inhibitors
()-Deprenyl (selegiline), developed as the first selective
inhibitor of monoamine oxidase type-B (MAO-B) in the early
60s, is widely used for the symptomatic treatment of PD in
combination with L-DOPA to inhibit dopamine catabolism (Larsen
and Boas, 1997; Przuntek et al., 1999). It has been considered a
promising candidate drug for neuroprotective therapy in early-
stage PD (Schapira and Olanow, 2004).
Selegiline protects dopaminergic neurons in the MPTP/MPP+
model of PD (Cohen et al., 1984; Heikkila et al., 1984; Mytilineou
and Cohen, 1985; Tatton and Greenwood, 1991; Koutsilieri et al.,
1994). This neuroprotective effect might be related to the
induction or potentiation of antioxidant enzymes (Carrillo et al.,
1991; Thiffault et al., 1995; Nakaso et al., 2006; Takahata et al.,
2006) or anti-apoptotic molecules (Tatton et al., 1996). The
neuroprotective effects of selegilinemight also involve its ability to
up-regulate neurotrophic factor synthesis, including that of GDNF.Selegiline increases the content of GDNF in the culture medium
from mouse astrocytes in a MAO-B-independent manner, as a
concentration of selegiline that completely inhibits MAO activity
has no effect on the content of neurotrophic factors (Mizuta et al.,
2000). In addition, desmethylselegiline, a selegiline metabolite,
also elevates GDNF mRNA and protein levels (Mizuta et al., 2000).
Intrastriatal injections of selegiline significantly enhance GDNF
mRNA expression in rats, whereas the same concentrations of
selegiline do not affect MAO-B activity (Tang et al., 1998).
Therefore, the effect of selegiline on GDNF expression seems to
be independent of its effect on MAO activity but is not clear
whether it involves the enhancement of the impulse mediated
release of catecholamines, the so called ‘‘catecholaminergic
activity enhancement’’ (CAE; Knoll, 1998).
Another MAO-B inhibitor, rasagiline (N-propargyl-(1R)-ami-
noindan), is used as monotherapy in PD and as adjunctive therapy
for patients receiving L-DOPA (Rabey et al., 2000; Parkinson Study
Group, 2002a). Rasagiline may slow the rate of progression of PD
(Siderowf and Stern, 2006) and displays neuroprotective activity in
in vivomodels of neurodegenerative diseases (reviewed by Youdim
et al., 2005). Severalmechanisms have been proposed to explain its
neuroprotective action (Mandel et al., 2005). Chronic low doses of
rasagiline administered to mice subsequently to MPTP rescue
dopaminergic neurons in the substantia nigra pars compacta via
activation of the Ras-PI3K-Akt survival pathway, suggesting that
rasagiline may possess disease-modifying activity (Sagi et al.,
2007). A possible disease-modifying activity of rasagiline is also
suggested by clinical trials with early PD patients (Parkinson Study
Group, 2004).
Rasagiline increases the mRNA and protein levels of GDNF in
SH-SY5Y neuroblastoma cells through the activation of NF-kB
(Maruyama et al., 2004). Rasagiline promotes neuronal survival via
the neuroprotective activity related to its propargyl moiety,
propargylamine, which elevates the gene expression levels of
GDNF and BDNF, and markedly reverses the apoptotic effects
induced by long-term serum withdrawal in SH-SY5Y neuroblas-
toma cells. In addition, it up-regulates the anti-apoptotic protein
Bcl-2, while down-regulating the pro-apoptotic proteins Bax, Bad
and Bim (Bar-Am et al., 2005).
7.1.4. Dopamine uptake inhibitor ()-BPAP
[R-()-1-(benzofuran-2-yl)-2-propylaminopentane] (()-
BPAP) was shown to inhibit catecholamine uptake (Shimazu
et al., 2003b) and has been considered a promising candidate drug
for the symptomatic treatment of PD because it enhances the
impulse-evoked release of catecholamines from isolated brain-
stem, and reverses motor deficits in an acute animal model of PD
(Knoll et al., 1999; Shimazu et al., 2001). In addition to its
catecholaminergic and serotoninergic activity enhancer effect, ()-
BPAP might act as a neuroprotective agent since it up-regulates
neurotrophic factor synthesis. ()-BPAP is able to increase both the
mRNA level and the amount of GDNF, NGF, and BDNF secreted to
the culture medium by mouse astrocytes (Ohta et al., 2002;
Shimazu et al., 2003a).
7.2. Glutamate antagonists
Glutamate receptors play crucial roles in the motor circuitry of
the basal ganglia. The abundance, structure, and function of striatal
NMDA receptors are altered by dopamine depletion, and further
modified by the pharmacological treatments used in PD (reviewed
by Hallett and Standaert, 2004). In animal models, NMDA receptor
antagonists are effective anti-parkinsonian agents and can reduce
themotor complications induced by chronic dopaminergic therapy
(reviewed by Hallett and Standaert, 2004). NMDA receptor
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and attenuate the dopamine/glutamate imbalance (Lannes and
Micheletti, 1997; Page et al., 2000; Peeters et al., 2002). In addition
to ameliorating PD symptoms, several glutamate antagonists have
shown neuroprotective effects in the nigrostriatal system.
Amantadine (1-aminoadamantane) is a NMDA receptor antago-
nist that has been used for the management of PD and, together
with its more potent congener memantine, displays neuroprotec-
tive properties in a large number of in vitro and in vivo models
(reviewed by Kornhuber et al., 1994; Parsons et al., 1999). In
addition to their activity as NMDA receptor antagonists, the
stimulation of GDNF expression can also contribute to their
influence on neuronal survival and protection. Both amantadine
andmemantine concentration dependently increase GDNF level in
the culture medium from C6 glioma cells with similar potency and
efficacy (Caumont et al., 2006a). Since the range of concentrations
that induce GDNF release from C6 cells are close to the clinically
relevant steady-state plasma concentrations in patients treated
with amantadine and memantine, these results show that the
neuroprotective effect of these drugsmay be related to their ability
to stimulate GDNF production by glial cells (Caumont et al., 2006a).
Ifenprodil, originally developed as an effective cerebral
vasodilator, was later reported to act as an NR2B-selective NMDA
receptor antagonist (reviewed by Williams, 2001). Along this line,
ifenprodil has been documented to elicit anti-parkinsonian effects
in animal models of PD (Mitchell et al., 1995; Nash et al., 1999,
2000) comparable to those observed with L-DOPA therapy (Nash
et al., 2000). Ifenprodil can also exert neuroprotective and/or
neurorestorative effects because it strongly enhances the produc-
tion of GDNF, BDNF and NGF in mouse astrocyte cultures, both at
the mRNA and protein level (Toyomoto et al., 2005).
Riluzole (2-amino-6-trifluoromethoxy benzothiazole), a Na+
channel blocker reported to be an antagonist of the excitatory
amino acid neurotransmission (Mizoule et al., 1985), is currently
used in the therapy of patients with amyotrophic lateral sclerosis
(Jackson et al., 2002). Riluzole alleviates the circling behaviour in
6-OHDA-treated rats and decreases the suppression of striatal
and nigral dopaminemetabolism (Barneoud et al., 1996). Riluzole
also delays the appearance of parkinsonian motor abnormalities
in a chronic monkey model of MPTP toxicity (Bezard et al., 1998),
and exerts neuroprotective and palliative effects on an acute
model in the same species (Benazzouz et al., 1995). In mice,
riluzole antagonizes the MPTP-induced decrease in dopamine,
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid
(HVA) levels in the striatum and, by immunohistochemistry,
riluzole was shown to protect against MPTP-induced neuronal
damage in the substantia nigra (Araki et al., 2001). Since MK-801
treatment prevents the MPTP-induced decrease in DOPAC levels,
but not in dopamine levels in the striatum (Araki et al., 2001), the
inhibition of NMDA receptors is not the only neuroprotective
action of riluzole against MPTP-induced striatal dopamine and
DOPAC depletion in mice. Indeed, some studies suggest that
riluzole may have direct antioxidant actions in cultured neurons
(Koh et al., 1999; Storch et al., 2000). In addition, riluzole might
exert neuroprotective effects, at least partially, via the induction
of neurotrophic factors as it stimulates the synthesis and release
of the neurotrophic factors GDNF, NGF and BDNF in cultured
mouse astrocytes (Mizuta et al., 2001), and significantly increases
GDNFmRNA and protein levels in C6 glioma cells (Caumont et al.,
2006b). This suggests that the regulation of GDNF transcription in
glial cells can contribute to the pharmacological properties of
riluzole and possibly to its neuroprotective effects on PD animal
models. The effects of riluzole on GDNF expression are inhibited
by PD98059, an inhibitor of the mitogen-activated protein kinase
(MAPK) kinase (also known as MAPK/ERK – extracellular signalregulated kinase – kinase or MEK). Interestingly, other works
show the pharmacological induction of GDNF expression and
release in glial cells through a MAPK/ERK kinase-dependent
pathway (Hisaoka et al., 2001, 2004; Koyama et al., 2003a), as
detailed below.
7.3. Anti-depressants, anti-psychotics and mood stabilizers
GDNF levels may be altered by anti-depressants (Hisaoka et al.,
2001), anti-psychotics (Shao et al., 2006) and mood stabilizers
(Angelucci et al., 2003; Castro et al., 2005). It has been
hypothesized that these drugs might exert their beneficial action
by regulating the synthesis and/or release of neurotrophic factors
(Angelucci et al., 2003; Saarelainen et al., 2003; Hashimoto et al.,
2004). Anti-depressants significantly increase GDNF mRNA
expression and GDNF release in a time- and concentration-
dependent manner in C6 cells, and amitriptyline treatment also
increases GDNF mRNA expression in rat astrocytes (Hisaoka et al.,
2001). Fluoxetine (Prozac) also increases GDNF mRNA expression
in cultured rat astrocytes, an effect prevented by ERK inhibitors
(Mercier et al., 2004).
In addition, GDNF release increases after exposure to amitripty-
line, clomipramine, mianserin, fluoxetine, and paroxetine, but not
after treatment with the non-anti-depressant psychotropic drugs
haloperidol, diazepam, and diphenhydramine (Hisaoka et al.,
2001). Although 5-HT, but not noradrenaline or dopamine,
increases ERK activation and GDNF release via 5-HT2A receptors,
ketanserin, a 5-HT2A receptor antagonist, has no effect on
amitriptyline-induced ERK activation (Hisaoka et al., 2004,
2007) suggesting that GDNF production induced by amitriptyline
is independent of monoamine signalling. Moreover, treatment
with amitriptyline rapidly increases ERK activity, as well as p38
MAPK and JNK activities. Both the amitriptyline-induced ERK
activation and GDNF mRNA expression are blocked by genistein, a
general protein tyrosine kinase inhibitor (Hisaoka et al., 2007). In
addition, acute amitriptyline treatment increases the phosphor-
ylation of CREB in C6 cells aswell as in human astrocytes, but not in
SH-SY5Y neuroblastoma cells (Hisaoka et al., 2008). These findings
indicate that ERK activation through protein tyrosine kinase
regulates anti-depressant-induced GDNF production, and that the
GDNF production in glial cells may be a novel action of this anti-
depressant drug, independent of monoamine signalling (Hisaoka
et al., 2007).
The atypical anti-psychotic drugs quetiapine and clozapine, as
well as the typical anti-psychotic haloperidol, increase the amount
of GDNF secreted from C6 glioma cells into the medium, after 48 h
incubation, without inducing changes in the intracellular content
of GDNF (Shao et al., 2006). These effects are observed at drug
concentrations starting at 10 mmol/L and, in agreement with the
findings by Hisaoka et al. (2001), haloperidol at a concentration of
1mmol/L does not cause a significant increase in GDNF secretion
(Shao et al., 2006).
Chronic treatment with lithium, probably the most effective
mood stabilizer, increases GDNF concentrations in the cortex, but a
decrease was found in the hippocampus of the Flinders Resistant
Line (Angelucci et al., 2003). In contrast, Fukumoto et al. (2001)
found no significant effects of lithium on GDNF levels.
Valproic acid (VPA) is a mood stabilizer and an anti-epileptic
drug (Perucca, 2002), and increasing evidence demonstrate that
VPA has neurotrophic effects in diverse cell types including
midbrain dopaminergic neurons. Chronic VPA administration for
14 days increases the expression of BDNF protein in the rat brain
but no changes were observed in the expression of GDNF following
VPA treatment (Fukumoto et al., 2001). In contrast, Castro et al.
(2005) reported significant concentration-dependent increases in
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48 h, but not for 24 h. These discrepancies can be due to different
time-courses for the induction of the two neurotrophic factors or to
differences in the models used (Castro et al., 2005). Moreover, VPA
pre-treatment protects midbrain dopaminergic neurons against
LPS- or MPP+-induced toxicity (Chen et al., 2006b). VPA-induced
survival of midbrain dopaminergic neurons in LPS-treated neuron-
glia cultures involves the inhibition of the release of pro-
inflammatory factors from microglia (Peng et al., 2005). Recently,
VPAwas reported to up-regulate the expression of GDNF and BDNF
in astrocytes and these effects may play a major role in mediating
VPA-induced neurotrophic effects on dopaminergic neurons (Chen
et al., 2006b). Although the mechanisms of VPA induction of
neurotrophic factors are not known, they might involve modifica-
tion of chromatin structure since VPAwas shown to directly inhibit
histone deacetylase (HDAC), an enzyme that catalyzes the removal
of acetyl groups from histones (Phiel et al., 2001).
PD patients suffer from impaired cognitive functions due to
disturbances in the dopaminergic system and hippocampal
atrophy (Jokinen et al., 2008 and references therein). Interestingly,
several studies demonstrate that VPA (Bredy et al., 2007; Bredy and
Barad, 2008) or pentyl-4-yn-VPA, a VPA analogue (Murphy et al.,
2001; Foley et al., 2004), facilitate learning and memory.
Accumulating evidence show that VPA and other HDAC inhibitors
can ameliorate deficits in synaptic plasticity and cognition in
several neurologic and psychiatric disorders (reviewed by Abel and
Zukin, 2008). This suggests that HDAC inhibitionmight represent a
promising therapeutic tool for the cognitive impairments related
to neurodegenerative diseases. Since GDNF can play a role in
learning and memory (detailed in Section 10), it is interesting to
note that the therapeutic potential of VPA for the treatment of
cognitive dysfunction in PD could also involve the VPA-induced
GDNF expression in the hippocampus. This effect could be indirect
or directly related to VPA’s action as an HDAC inhibitor since it is
known that histone modifications around individual BDNF gene
promoters increase BDNF mRNA expression and are associated
with long-term memory (Bredy et al., 2007).
By suppressing neuroinflammation, stimulating the release of
trophic factors from astrocytes, and improving cognitive dysfunc-
tions, VPA can prove to be an effective therapeutic tool in PD and
possibly in other neurodegenerative diseases.
7.4. Anti-dementia drugs
FK960, a novel anti-dementia drug, was found to selectively
increase GDNF mRNA and protein levels in cultured rat astrocytes,
since the mRNA levels of other neurotrophic factors (BDNF, NGF,
NT-3, FGF-2) were not changed (Koyama et al., 2004). The FK960-
induced increase in GDNFmRNA ismediated by the activation of c-
Fos and CREB with the ERK signal playing a key role in both the c-
Fos expression and CREB phosphorylation (Koyama et al., 2004).
Dexamethasone and pyrrolidine dithiocarbamate, which inhibit
the NF-kB mediated increase in astrocytic GDNF expression
(Koyama et al., 2003a), do not affect the FK960-induced increase
in GDNF expression in cultured astrocytes indicating that it is
unlikely that NF-kB plays a role in the effect of FK960 on GDNF
expression (Koyama et al., 2004).
7.5. Immunophilin ligands
Immunophilin ligands are immunosuppressive agents that bind
to members of the FK506-binding proteins (FKBPs) (Steiner et al.,
1992), followed by the inhibition of calcineurin by the immuno-
philin/FKBP complex and inhibition of cytokine synthesis, thus
preventing T-cell activation (Liu et al., 1992). Some of theseimmunophilin ligands may enhance and/or mimic neurotrophic
factor functions, such as promotion of neuronal survival or
prevention of neuronal degeneration (reviewed by Pong and
Zaleska, 2003). Since the blood–brain barrier is more permeable to
immunophilin ligands than to neurotrophic factors, they are a
promising treatment for neurodegenerative diseases, and may be
more useful than neurotrophic factors as therapeutic drugs against
PD progression. Nevertheless, current clinically available immu-
nophilin ligands, including FK506 and cyclosporine A, are
immunosuppressive, which limits their chronic use. However,
neither calcineurin inhibition nor binding to FKBP-12 were found
to be necessary for the neurotrophic effects of immunophilin
ligands (Steiner et al., 1997; Costantini et al., 2001; Guo et al., 2001;
Klettner et al., 2001; Zhang et al., 2001a; Tanaka et al., 2002b). This
fact, together with the neuroprotective effects of immunophilin
ligands in models of neurodegenerative disorders (reviewed by
Pong and Zaleska, 2003), has led to the design of small ligands that
bind to immunophilins, but are not immunosuppressive since they
do not interact with calcineurin (e.g. Armistead et al., 1995;
Adalsteinsson and Bruice, 2000).
In addition to its function in the immune system, FK506
(Tacrolimus) also exhibits neuroprotective and neurotrophic
effects, including stimulation of axonal re-growth and enhance-
ment of functional recovery in a variety of neurodegenerative
disease models (reviewed by Sosa et al., 2005). Several studies
report that FK506 and related non-immunosuppressive immuno-
philin ligands, such as GPI-1046 and V10367, have neurotrophic/
neuroprotective effects on dopaminergic neurons followingMPTP-
or 6-OHDA-induced lesion (Steiner et al., 1997; Costantini et al.,
1998, 2001; Ross et al., 2001; Zhang et al., 2001a; Tanaka et al.,
2002a). Neurotrophic effects to dopaminergic neurons are also
observed in vitro (Costantini and Isacson, 2000; Guo et al., 2001).
Some of the neurotrophic and neuroprotective effects of FK506
might be a consequence of the stimulation of GDNF expression as
FK506 (as well as GPI-1046) significantly increases GDNF content
in the mouse substantia nigra, but not in the striatum, when
administered subcutaneously for 7 days. In addition, FK506
increases striatal BDNF content, suggesting that the immunophilin
ligand-induced neurotrophic-like activity may be dependent on
GDNF or BDNF expression (Tanaka et al., 2003). Moreover,
treatment of U251 human glioma cells with FK506 (GPI-1046 or
V10367) promotes GDNF release (Tanaka et al., 2004). Despite the
therapeutic potential of FK506 in ameliorating neuronal injury,
and the fact that FK506 penetrates the blood–brain barrier
reasonably well, it cannot be used in therapy for neurological
disorders due to its immunosuppressive effects. Nevertheless, it
has been used as a model to develop new immunophilin ligands
lacking the limitations of FK506 for clinical application.
Leucine-isoleucine (Leu-Ile), a hydrophobic dipeptide that
partially resembles the site on FK506 that binds to immunophilin
(Schreiber, 1991), induces GDNF expression both in vitro and in
vivo. Leu-Ile significantly increases GDNF and BDNF contents in the
conditioned medium from cultured hippocampal neurons after
24 h (Nitta et al., 2004). In mesencephalic cell cultures, Leu-Ile
protects both dopaminergic and non-dopaminergic neurons
against cell death that naturally occurs in low density cultures,
but the effect is lost when cell cultures are prepared from mice
lacking the GDNF or BDNF gene (Nitta et al., 2004). When
administered intraperitoneally (ip) or icv once a day for 5 days,
Leu-Ile increases GDNF and BDNF content in the striatum of mice.
In addition, peripheral administration of Leu-Ile inhibits dopami-
nergic denervation induced by an intrastriatal unilateral injection
of 6-OHDA, and reduces rotational behaviour after methamphe-
tamine (Nitta et al., 2004). The ability of Leu-Ile to cross the blood-
brain barrier and to promote GDNF expression without exhibiting
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treatment of PD or other neurodegenerative diseases. Moreover,
since GDNF has been implicated as a negative regulator of drug-
and alcohol-induced dependence (reviewed by Ron and Janak,
2005) and Leu-Ile induces GDNF expression, it has been proposed
as a therapeutic agent for addiction (Niwa et al., 2007).
7.6. Hormones with neurotrophic activity
7.6.1. Melatonin
Pharmacological doses of melatonin have been shown to be
neuroprotective in the 6-OHDA and in the MPTP models of PD (Joo
et al., 1998; Thomas and Mohanakumar, 2004). Delivery of
melatonin at physiological doses by mini-pump also protects
against a 6-OHDA-induced decrease in mitochondrial complex I
activity (Dabbeni-Sala et al., 2001). Furthermore, 6-OHDA-lesioned
animals treatedwithahighphysiological doseofmelatoninexhibit a
significant reduction in apomorphine-induced rotational behaviour
and concomitant protection of striatal TH immunoreactivity
(Sharma et al., 2006). The neuroprotection promoted by melatonin
is thought to involve its antioxidant and free radical scavenging
effects (Reiter et al., 2004; Rodriguez et al., 2004; Vega-Naredo et al.,
2005). However, the neuroprotective properties ofmelatoninmight
also be mediated through GDNF up-regulation. A marked, con-
centration-dependent, increase in GDNFmRNA and protein levels is
observed in rat C6 cells following treatment with physiological
(0.05–1 nM) or higher (10 and 100 nM) concentrations ofmelatonin
(Armstrong and Niles, 2002). The melatonin receptor (MT) 1 has
been implicated, as the selective MT2 antagonist did not block the
melatonin-induced increase in GDNF expression (Armstrong and
Niles, 2002). Low physiological concentrations of melatonin also
caused a significant induction of GDNFmRNAexpression in a neural
stemcell line (Niles et al., 2004). Intrastriatal injections ofmelatonin
significantly enhance GDNF mRNA expression in the striatum at
threshold doses lower than those needed to alter the antioxidant
enzymesystems (Tangetal., 1998) andGDNF levelsare alsoelevated
in the locus coeruleus of melatonin-treated rats (Chen et al., 2003).
Melatonin also induces astroglial GDNF expression in the mouse
hippocampus (Lee et al., 2006).
Induction of GDNF bymelatoninmay be a direct effect mediated
by activation of melatonin G-protein-coupled receptors, which are
negatively coupled to the adenylyl cyclase-cAMP pathway, thereby
mediating the suppression of cAMP synthesis (Dubocovich et al.,
2003).Asa result, the activationof these receptors leads todecreases
in protein kinase (PK) A activity and protein phosphorylation, with
consequent changes in the activity of transcription factors and gene
expression (Masana and Dubocovich, 2001). In fact, elevation of
cAMP levels with forskolin, dibutyryl-cAMP (db-cAMP) or 3-
isobutyl-1-methylxanthine (IBMX) represses GDNF secretion in
C6 cells (Suter-Crazzolara and Unsicker, 1996; Verity et al., 1998).
Therefore, it is likely that a decrease in cAMPmediatedbymelatonin
receptors may induce GDNF expression.
Melatonin can also increase GDNF expression via PKC since it
can activate PKC directly (Anton-Tay et al., 1998; Hunt et al., 2001).
Interestingly, melatonin may induce GDNF expression through
modulation of PKA and PKC activities, although PKA and PKC seem
to have opposing effects on GDNF expression. In addition,
melatonin, via the MT1 receptor, can activate the MAPK–ERK
pathway (Witt-Enderby et al., 2000), which has been shown to up-
regulate the transcription of vascular endothelial growth factor via
specificity protein (Sp)1 and activating protein (AP)-2 sites
(Milanini et al., 1998). This is relevant as both Sp1 and AP-2
binding sites are present in the GDNF promoter (Woodbury et al.,
1998; Baecker et al., 1999) thereby providing another means by
which melatonin can induce GDNF up-regulation.Collectively, the above data show that the stimulation of GDNF
expression may be involved in some of the neuroprotective effects
of melatonin.
7.6.2. Vitamin D3
Several studies have shown that 1,25-dihydroxyvitamin D3, the
active form of vitamin D3, enhances endogenous GDNF expression.
Although no changes in GDNF mRNA expression in rat glial cells in
culture were observed by Remy et al. (2001) after treatment with
1,25-dihydroxyvitamin D3, it is a potent inducer of GDNF mRNA
expression in C6 cells (Naveilhan et al., 1996). It also increases
extracellular GDNF protein levels in C6 cells (Verity et al., 1998) as
well as in the glioblastoma cell line U-87MG,while having no effect
on a neuroblastoma cell line (Verity et al., 1999). These
observations suggest that the effect of 1,25-dihydroxyvitamin
D3 on GDNF expression might be cell type dependent. There are
also evidences that 1,25-dihydroxyvitamin D3 increases GDNF
levels in vivo (Wang et al., 2000; Sanchez et al., 2002). This
neurotrophic effect might contribute to the finding that pre-
treatment with 1,25-dihydroxyvitamin D3 protects against 6-
OHDA-mediated depletion of dopamine and its metabolites in the
substantia nigra, while in vitro it protects primary mesencephalic
neurons against 6-OHDA- or H2O2-induced cell death (Wang et al.,
2001b). An interesting observation is that rats born from vitamin
D3-deficient dams have profound alterations in the brain at birth,
including reductions in brain content of GDNF andNGF (Eyles et al.,
2003), and exhibit persistent changes in the adult brain (Feron
et al., 2005).
7.6.3. Oestrogen
Oestrogens have been shown to interfere with embryonic
neuronal differentiation and survival of nigrostriatal dopaminergic
neurons (reviewed by Kipp et al., 2006), and to regulate the
expression of neurotrophic factors, which might mediate their
neuroprotective effects (reviewed by Morale et al., 2006). Pre-
treatment with oestrogen provides significant neuroprotection
against superoxide-, H2O2- or glutamate-induced neurotoxicity in
primary neuronalmesencephalic cultures (Sawada et al., 1998a). In
vivo studies show beneficial effects of oestrogens against the
toxicity induced by 6-OHDA (Murray et al., 2003) or MPTP (Dluzen
et al., 1996; Callier et al., 2001; Ramirez et al., 2003; D’Astous et al.,
2004; Jourdain et al., 2005) in the nigrostriatal system. Oestrogens
rescue spinal motoneurons from AMPA-induced toxicity through
an increase in the production and release of GDNF by astrocytes
(Platania et al., 2005). Oestrogens also increase the expression of
GDNF in hypothalamic cell cultures, in neurons but not in
astrocytes, through non-classical oestrogen signalling as the
application of the nuclear receptor antagonist ICI 182,780 does
not prevent oestrogen-induced GDNF expression (Ivanova et al.,
2002). The oestrogen-induced GDNF up-regulation in hypotha-
lamic cells is prevented by cAMP/PKA and calcium signalling
antagonists whereas inhibitors of PKC, PI3K or MAPK are
ineffective, suggesting that intracellular Ca2+ and cAMP/PKA
signalling are required for GDNF increases in neuronal cells in
response to oestrogen. Both cascades converge to the transcription
factor CREB (Nichols et al., 1992), so it is relevant that the promoter
region of GDNF gene contains a binding site for CREB (Woodbury
et al., 1998; Baecker et al., 1999). Oestrogen-dependent regulation
of GDNF also occurs in themidbrain (reviewed by Kipp et al., 2006).
Using neonatal midbrain astroglial and embryonic neuronal
cultures oestrogen was reported to induce GDNF transcription
in astrocytes but not in neurons, an effect that was not prevented
by ICI 182,780 but was abrogated by interrupting the intracellular
Ca2+-signalling or the MAPK signal transduction system (reviewed
by Kipp et al., 2006).We should alsomention that preliminary data
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GDNF levels in postnatal cultures from ventral midbrain and
potentiates L-DOPA- or H2O2-induced GDNF up-regulation in the
same cultures. In agreement with the results reviewed by Kipp
et al. (2006), we found that oestrogen-inducedGDNF up-regulation
was not affected by ICI 182,780 nor abolished by the non-permeant
(conjugated to albumin) form of oestrogen (unpublished results).
Given the relevance of oestrogen to dopaminergic neurons of
the nigrostriatal system (reviewed by Kipp et al., 2006) and their
positive impact on GDNF expression (Ivanova et al., 2002; Platania
et al., 2005), the effect of oestrogen exposure on GDNF levels in the
nigrostriatal system deserves further investigation, both in naı¨ve
animals and in PD models.
8. Inducers of GDNF expression brought from the traditional
medicine
Growing evidence indicate that Chinese herbs and extracts
attenuate the degeneration of dopaminergic neurons and amelio-
rate the parkinsonism induced byMPTP and 6-OHDA (reviewed by
Chen et al., 2007). Several mechanisms have been proposed to
contribute to the neuroprotective effect of Chinese herbs and
extracts. These include their function as antioxidants to alleviate
oxidative stress, inhibitors of MAO-B to decrease neurotoxicity,
scavengers of free radicals, chelators of harmful metals, mod-
ulators of cell survival genes and apoptotic signals (reviewed by
Chen et al., 2007). As a result, Chinese herbs and extracts are
receiving increasing attention as therapeutic agents for the
treatment of PD patients. The efficacy and safety of their use in
adjunct ormonotherapy in PDmanagement is under consideration
(reviewed by Chung et al., 2006). Unfortunately, the effect onGDNF
expression has not yet been addressed for many of them. It would
be very interesting to investigate if these and other herbal extracts
are able to increase GDNF expression, as well as whether their
protective effects in PD animal models are mediated, or not, by the
up-regulation of GDNF expression. Next we revise the sparse
literature on GDNF induction by herbs or herbal compounds.
Rehmannia glutinosa, a traditional Chinese medicine herb
frequently used in the therapy of dementia, induces GDNF gene
expression in C6 cells and in primary cortical astrocytes (Yu et al.,
2006). The effect of Rehmannia glutinosa on GDNF mRNA up-
regulation in C6 cells is completely attenuated by the presence of a
PKC inhibitor and a MEK1 inhibitor. However, none of the PKC
inhibitors significantly changes the effect of Rehmannia glutinosa
on ERK1/2 phosphorylation, suggesting that the stimulation of
GDNF gene expression by Rehmannia glutinosa could be indepen-
dently up-regulated through PKC and ERK1/2 pathways in C6 cells
(Yu et al., 2006).
Smilagenin is a compound extracted from Rhizoma anemar-
rhenae and Radix asparagi, medicinal herbs frequently used in the
traditional Chinese medicine. A recent work shows that smila-
genin, when added prior to MPP+, protects culturedmesencephalic
dopaminergic neurons against MPP+-induced toxicity. GDNF
mRNA levels, but not those of GFRa1 or Ret, are markedly
elevated in the presence of smilagenin. Moreover, the neuropro-
tective effect is partially lost in the presence of GDNF and/or GFRa1
antibodies (Zhang et al., 2008).
Ibogaine is a psychoactive compound extracted from Taber-
nanthe iboga and used for decades in African folklore medicine and
rituals. Many studies indicate that ibogaine reduces craving and
withdrawal symptoms of several drugs of abuse (reviewed by Ron
and Janak, 2005). This anti-addiction drug increases GDNF levels in
dopaminergic-like SH-SY5Y cells and up-regulates the GDNF
pathway as assessed by the phosphorylation of the GDNF receptor
Ret and the downstream kinase ERK1 (He et al., 2005). A MEKinhibitor inhibits ibogaine-induced GDNF up-regulation (He and
Ron, 2006). In addition, after systemic administration to rodents,
ibogaine increases GDNF expression in the VTA (He et al., 2005).
Since GDNF has been implicated as a negative regulator of drug and
alcohol addiction (reviewed by Ron and Janak, 2005), the effect of
ibogaine on GDNF expression likely contributes to its positive
impact on the treatment of addiction. However, despite its
properties, ibogaine is not approved as an addiction treatment
because it induces hallucinations.
Finally, royal jelly, a honeybee secretion with a variety of
biological activities, selectively stimulates, after oral administra-
tion, the GDNFmRNA expression in the hippocampus and cortex in
the adult mouse. The expression of other neurotrophic factors or
GFRa1 is not affected (Hashimoto et al., 2005b). Administration of
royal jelly has no effect on GDNF expression in the midbrain, but
the effect on the striatum was not addressed (Hashimoto et al.,
2005b).
Given the accumulating evidence on the neuroprotective effect
that herbs from the traditional medicine have in animal models of
PD, and the ability to induce GDNF expression that some of them
have already shown, it may prove useful to study their impact on
GDNF levels in the nigrostriatal system, as they might reveal to be
important GDNF inducers.
9. From receptors to GDNF gene: signalling pathways
controlling GDNF expression
Signal transduction pathways might also constitute targets to
neuroprotective therapies. From the data reviewed above, a view
emerges involving MAPK, PKC, PKA and Ca2+ leading to activation
of several transcription factors, some of which are known to have
response elements in the promoter of GDNF gene (Fig. 3).
Moreover, some of those signalling pathways control the release
of GDNF.
9.1. Role of MAPK
A role for the MAPK pathway in the regulation of GDNF
transcription is supported by studies showing that agents such as
riluzole, amitriptyline, ET-1 or the medicinal herb Rehmannia
glutinosa, acting in different receptor systems, induce GDNF
expression through the activation of the MAPK pathway. For
instance, the glutamate receptor antagonist riluzole is able to
promote GDNF expression in a MEK-dependent manner since the
inhibitor PD98059 completely reverses that effect (Caumont et al.,
2006b). This inhibitor also prevents the increases in astrocytic
GDNF mRNA induced by ET-1 (Koyama et al., 2003a). The
amitriptyline-evoked increase in both GDNF mRNA and GDNF
release are selective and completely inhibited by MEK inhibitors
(Hisaoka et al., 2001). Indeed, treatment with amitriptyline rapidly
increases ERK activity, as well as p38 MAPK and JNK activities.
Furthermore, different classes of anti-depressants also rapidly
increase ERK activity. The extent of acute ERK activation and GDNF
release are significantly correlated to each other for individual
anti-depressants, suggesting an important role for acute ERK
activation in GDNF production (Hisaoka et al., 2007). Additionally,
the stimulation of GDNF expression in C6 cells by Rehmannia
glutinosa is attenuated by the presence of a MEK1 inhibitor
indicating that GDNF can be up-regulated through ERK1/2
pathways in C6 cells (Yu et al., 2006).
A direct relationship between the activation of the MAPK
pathway and the expression of GDNF was not established for VPA
or melatonin. Nevertheless, a correlation between the ability to
increase GDNF levels and to activate the MAPK pathway can be
depicted. VPA has been shown to activate the MAPK–ERK pathway
Fig. 3. Overview of factors regulating GDNF expression and the signalling pathways involved. Riluzole, amitriptyline, melatonin, and Rehmannia glutinosa activate the MAPK
pathway, a pathway thatmay induceGDNF expression throughactivationof Sp1 andAP-2 binding sites in theGDNFpromoter.Melatonin and oestrogen induceGDNFexpression
byactingonthecAMP/PKAsignallingpathway.Thispathwayincreases theactivityof the transcription factorCREB, a transcription factorwithabindingsite in thepromoter region
of the GDNF gene. PMA, TPA, or Rehmannia glutinosa promote GDNF expression through a PKC-dependent mechanism. Agents that increase cytoplasmatic Ca2+ levels such as
A23187, ionomycinor thapsigarginareable toenhanceGDNFexpression, in the caseof thapsigargin thiseffect ispartiallymediatedbytheMAPKpathway. () indicatesanegative
modulatory effect, arrowswith questionmark indicate an unknownmechanism and dotted lines indicate unknown links. Abbreviations: PKA, protein kinase A;MAPK, mitogen-
activated protein kinase; PKC, protein kinase C; GDNF, glial cell line-derived neurotrophic factor; VPA, valproic acid; FGF-2, basic fibroblast growth factor; IBMX, 3-isobutyl-1-
methylxanthine; CREB, cyclic AMP response element binding protein; NF-kB, nuclear factor-kB; Sp1, specificity protein 1; AP-2, activator protein 2.
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suggesting that this mechanism could be responsible for the
VPA-induced GDNF up-regulation observed in other studies
(Castro et al., 2005; Chen et al., 2006b). Melatonin, also known
to increase the expression of GDNF (Tang et al., 1998; Armstrong
and Niles, 2002; Chen et al., 2003; Lee et al., 2006), is able, via the
MT1 receptor, to activate the MAPK–ERK pathway (Witt-Enderby
et al., 2000).
The increase of GDNF expression mediated by the activation of
the MAPK–ERK pathway is likely related to the activation of Sp1
and AP-2 binding sites in the GDNF promoter (Woodbury et al.,
1998; Baecker et al., 1999) since this signalling pathway has been
shown to up-regulate the transcription of vascular endothelial
growth factor via Sp1 and AP-2 sites (Milanini et al., 1998).
9.2. Role of PKC
PKC plays a key role in gene activation and production of GDNF.
The phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA),
which activates PKC, increases GDNF mRNA levels in primary rat
glial cells in culture (Remy et al., 2001). In fact, TPA increases the
activity of the GDNF promoter (Grimm et al., 1998). Interestingly,
activation of PKC by TPA enhances the neurotrophic effects of glial
conditioned medium on dopaminergic neurons (Engele and
Lehner, 1995), an effect possibly related to increased GDNF
expression. These results are consistentwith the finding that GDNFlevels increase after activation of PKC in C6 cells (Matsushita et al.,
1997; Verity et al., 1998; Nishiguchi et al., 2003). In addition,
phorbol myristate acetate (PMA), another activator of PKC,
increases GDNF mRNA levels in cultured Schwann cells (Kinameri
andMatsuoka, 2003). In contrast, after exposure to PKC inhibitors a
dramatic down-regulation of GDNF mRNA occurs in human
astrocyte cell cultures (Moretto et al., 1996). Moreover, GDNF
mRNA up-regulation induced by the traditional Chinese medicine
herb Rehmannia glutinosa in C6 cells is inhibited by R0-31-8220, a
pan-specific PKC inhibitor, thus supporting the involvement of PKC
in the control of GDNF gene expression by extracts of this herb (Yu
et al., 2006). The increase in GDNF expression promoted by
melatonin can also occur via PKC, as this kinase can be directly
activated by melatonin (Anton-Tay et al., 1998; Hunt et al., 2001).
Interestingly, melatonin may induce GDNF expression also
through modulation of PKA activity, although PKA and PKC seem
to have opposing effects on GDNF expression.
9.3. Role of PKA
Treatments that elevate cellular cAMP levels (e.g. forskolin,
IBMX) or the permeant analogue db-cAMP, have no effect on GDNF
mRNA levels (Matsushita et al., 1997; Kinameri and Matsuoka,
2003) and inhibit GDNF release in C6 cells (Suter-Crazzolara and
Unsicker, 1996; Verity et al., 1998), while stimulating GDNF
release in U-87MG glioblastoma and SK-N-AS neuroblastoma cells
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observation that cAMP enhances the activity of the GDNF promoter
(Grimm et al., 1998), suggest that the impact of cAMP/PKA
pathway on GDNF expression might be dependent on the cell type
and/or on the interaction of different signalling pathways.
Whereas elevated cellular cAMP levels induce no change in GDNF
mRNA levels, they strongly stimulate GFRa1 and Ret mRNA
expression in primary rat glial cells in culture (Remy et al., 2001)
suggesting that high levels of cAMP might enhance GDNF
signalling through increased expression of its receptors instead
of increasing ligand availability.
In one hand, the negative coupling of GDNF expression and
cAMP levels is in accordance with the ability of melatonin to
increase GDNF expression. Melatonin activates G-protein-coupled
MT receptors, which are negatively coupled to the adenylyl
cyclase-cAMP pathway, resulting in the decrease of cAMP
synthesis and PKA activity (Dubocovich et al., 2003). On the other
hand, GDNF up-regulation induced by oestrogen in hypothalamic
neurons in culture is prevented by cAMP/PKA antagonists
supporting a role for the activation of the cAMP/PKA pathway in
GDNF up-regulation in response to oestrogen (Ivanova et al., 2002).
This regulatory effect mediated by the cAMP/PKA signalling
pathway increases the activity of the transcription factor CREB
(Nichols et al., 1992). The ability of the cAMP/PKA signalling
pathway to increase GDNF expression is consistent with the
presence of a binding site for the transcription factor CREB in the
promoter region of the GDNF gene (Woodbury et al., 1998; Baecker
et al., 1999).
9.4. Role of Ca2+
Several evidences suggest that increased intracellular free Ca2+
levels are involved in GDNF transcription, and these observations
might account for both the activity-dependent GDNF expression
and the injury-induced GDNF up-regulation. Ca2+ ionophores, like
A23187 or ionomycin, increase GDNF levels in C6 cells (Verity
et al., 1998; Nishiguchi et al., 2003) and GDNF mRNA levels in
cultured Schwann cells (Kinameri and Matsuoka, 2003), but have
no effect on GDNF release in U-87MG glioblastoma cells (Verity
et al., 1999). The involvement of Ca2+ in GDNF expression is also
demonstrated by a study showing that thapsigargin-induced
endoplasmic reticulum Ca2+ discharge triggers GDNF mRNA
expression in C6 cells through both MAPK-dependent and -
independent pathways, but not the NF-kB pathway (Oh-Hashi
et al., 2006).
The contribution of intracellular Ca2+ to the stimulation of
GDNF transcription is also supported by data showing that, in
astrocyte cultures, oestrogen-induced GDNF increase is abolished
when intracellular Ca2+-signalling is inhibited with BAPTA, a
chelator of intracellular Ca2+ stores (reviewed by Kipp et al., 2006).
Furthermore, BAPTA blocks dopamine- and ET-1-stimulated
increases in GDNF transcript (Kinor et al., 2001; Koyama et al.,
2003a).
9.5. Transcription factors
9.5.1. Role of NF-kB
H2O2 increases GDNF mRNA levels in rat astrocytes (Yamagata
et al., 2002; Koyama et al., 2003a) and induces GDNF release
(Verity et al., 1998; Yamagata et al., 2002). H2O2 also up-regulates
GDNF mRNA and protein levels in substantia nigra neuron-glia cell
cultures thereby protecting dopaminergic neurons from H2O2-
induced toxicity (Saavedra et al., 2006). These results are
consistent with the observation that H2O2 activates the transcrip-
tion factor NF-kB (Meyer et al., 1993), and with the presence of abinding sequence for NF-kB on GDNF promoter (Woodbury et al.,
1998; Baecker et al., 1999; Tanaka et al., 2000). In fact, H2O2-
induced GDNF expression in cultured astrocytes is prevented by
inhibitors of NF-kB activation (Koyama et al., 2003a), and GDNF
secretion from C6 cells is repressed by treatment with dexa-
methasone, which inhibits the activation of NF-kB (Verity et al.,
1998). Interestingly, the trophic effects of glial conditioned
medium on dopaminergic neurons decrease in the presence of
dexamethasone (Engele and Lehner, 1995).
In addition to H2O2, also rasagiline increases GDNF mRNA and
protein levels through the activation of NF-kB (Maruyama et al.,
2004). Rasagiline induces the phosphorylation of the inhibitory
subunit (IkB) of NF-kB, and the translocation of the active p65
subunit from the cytoplasm to the nucleus in SH-SY5Y neuro-
blastoma cells. Inhibition of IkB kinase simultaneously suppresses
the activation of NF-kB and the increase in GDNF expression
induced by rasagiline, further supporting the involvement of the
NF-kB pathway in the regulation of GDNF levels by rasagiline
(Maruyama et al., 2004).
9.5.2. Role of CREB
Leu-Ile stimulates GDNF expression in neuronal hippocampal
cultures through mechanisms involving the activation of the heat-
shock protein (Hsp)90/Akt/CREB signalling pathway (Cen et al.,
2006). There is enhanced interaction between phospho-Akt and
Hsp90 and an Hsp90 inhibitor prevents the Leu-Ile-induced
increase in CREB protein phosphorylation, indicating that CREB
is a downstream target of Hsp90/Akt signalling. In addition, Leu-Ile
increases the binding activity of phospho-CREB to CRE, and
inhibition of CREB blocks the increase in GDNF levels induced by
Leu-Ile. These results show that CREB plays a key role in
transcriptional regulation of GDNF expression upon Leu-Ile
treatment (Cen et al., 2006). Similarly, FK960 induces GDNF
expression in a CREB-dependent mode (Koyama et al., 2004). VPA
activates CREB in the rat hippocampus and frontal cortex (Einat
et al., 2003), so it can promote GDNF expression through
mechanisms associated with the CREB pathway. The anti-
depressant amitriptyline might also induce GDNF expression in
a CREB-dependent manner as it increases the levels of phospho-
CREB (Hisaoka et al., 2008). Moreover, enriched environment
increases the phosphorylation of CREB and induces GDNF
expression (Young et al., 1999), and these two events might be
related as a binding site for the transcription factor CREB is present
in the promoter region of the GDNF gene (Woodbury et al., 1998;
Baecker et al., 1999).
9.6. A GDNF loop?
Auto-regulation of growth factor expression and secretion has
been documented, namely for BDNF, which positively regulates its
expression (Xiong et al., 2002), secretion (Canossa et al., 1997), and
the dendritic targeting of its mRNA (Righi et al., 2000). Very
recently, the induction of a long-lasting auto-regulatory cycle by
which GDNF positively regulates its own expression was first
described in SH-SY5Y cells exposed to ibogaine, and this
mechanism was suggested to explain the long-lasting actions of
ibogaine on GDNF expression (He and Ron, 2006). The up-
regulation of GDNF expression via GDNF itself needs further
investigation, but some observations support the finding reported
by He and Ron (2006).
As previously mentioned, the MAP kinase pathway has been
shown to up-regulate the transcription of vascular endothelial
growth factor via the Sp1 and AP-2 binding sites (Milanini et al.,
1998), and the analysis of the promoter region of the human GDNF
gene reveals putative Sp1 and AP-2 transcription factor binding
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regulatory increase in GDNF expression is inhibited by a MEK
inhibitor (He and Ron, 2006), the activation of the MAPK pathway
can contribute to the positive regulation of GDNF expression by
itself, via the Sp1 and AP-2 transcription factor binding sites within
its promoter.
On the other hand, several reports show that GDNF is able to
induce CREB phosphorylation in different systems (Feng et al.,
1999; Trupp et al., 1999; Hayashi et al., 2000; Pezeshki et al., 2001;
Yang and Nelson, 2004; Iwase et al., 2005), including Ret-deficient
cells (Poteryaev et al., 1999). Moreover, a binding site for the
transcription factor CREB is present in the promoter region of the
GDNF gene (Woodbury et al., 1998; Baecker et al., 1999).
In addition, GDNF promotes NF-kB activation in several models
(Hayashi et al., 2000; Kalechman et al., 2003; Takahashi et al.,
2004), namely by increasing the degradation of IkB, the protein
inhibitor of NF-kB activation (Kalechman et al., 2003), and the
involvement of this transcription factor in GDNF expression has
been strongly suggested, as discussed before.
9.7. Negative regulation of GDNF expression
To understand how the endogenous GDNF expression is
regulated it is necessary not only to uncover the mechanisms by
which several molecules trigger GDNF up-regulation, but also howFig. 4.Mechanisms of repression of GDNF expression and signalling. (Top panel) Molecule
action have not yet been characterized appear with a dotted inhibition signal. In gener
Mechanisms of repression of GDNF signalling. The panel A represents an ongoing GDNF s
represents the down-regulation of GDNF signalling induced by Gas1, as denoted by the in
Panel C shows the inhibition of the GDNF-induced activation of the MAPK pathway in the
the GDNF–GFRa1 complex. The pentameric signalling complex GDNF–(GFRa1)2–(Ret)2 (
repression during development (Section 3) are also absent. Green circles indicate tyro
indicative of unphosphorylated tyrosine residues. Gas1 inhibits the phosphorylation ofGDNF expression can be repressed (Fig. 4). This can be a useful tool
for both up- and down-regulation strategies. The literature on
GDNF repression is considerably sparse when compared to the
number of reports on molecules or conditions that induce GDNF
expression, as well as their mechanisms of action. Despite this, and
the fact that in many cases themechanism of repression is unclear,
this issue deserves attention and therefore this section will focus
on mechanisms of GDNF repression.
Reactive oxygen/nitrogen species may activate NF-kB
(reviewed by Gloire et al., 2006), and the involvement of NF-kB
in GDNF expression is strongly suggested (Verity et al., 1998;
Woodbury et al., 1998; Baecker et al., 1999; Tanaka et al., 2000;
Koyama et al., 2003a; Maruyama et al., 2004). Therefore, one
should expect that molecules that reduce oxidative stress, or
inactivate NF-kB, would repress GDNF expression. In fact,
treatment with the synthetic glucocorticosteroid methylpredni-
solone sodium succinate (MPSS) after spinal cord injury suppresses
GDNF expression (Nakashima et al., 2004). In addition, ONO-1714,
a newly developed specific inhibitor of inducible nitric oxide
synthase (iNOS), diminishes the early stage production of GDNF
upon spinal cord injury (Nakashima et al., 2005). Moreover,
hyperbaric oxygen treatment reduces iNOS and GDNF mRNA and
protein expression after spinal cord lesion due to the attenuation of
hypoxic insult (Yu et al., 2004). These data are consistent with the
observation that NO donors increase GDNF in C6 cells (Verity et al.,s involved in the down-regulation of GDNF expression. Thosewhosemechanisms of
al, the repression of GDNF expression seems to occur in glial cells. (Bottom panel)
ignalling, with consequent activation of the PI-3K and/or MAPK pathway(s). Panel B
hibition of Ret phosphorylation and consequent supression of PI-3K/Akt signalling.
presence of Lrig1 due to the absence of Ret recruitment to lipid rafts in response to
Schlee et al., 2006) was omitted for simplicity. To simplify, themechanisms of GDNF
sine residues that become phosphorylated upon Ret activation. Yellow circles are
the Ret residue tyrosine (Y) 1062.
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ischemic/hypoxic injury (Wei et al., 2000; Miyazaki et al., 2001;
Ikeda et al., 2002).
Another molecule found to inhibit GDNF expression is IL-10. IL-
10 negatively regulates GDNF production in rat glomerular
mesangial cells as the maximal GDNF expression occurs in the
presence of a low amount of IL-10 and, conversely, a low GDNF
production occurs when IL-10 production is optimal. In addition,
neutralizing IL-10 increases GDNF at time points where increased
levels of IL-10 are produced, but addition of IL-10 inhibits GDNF
secretion (Kalechman et al., 2003). This is further supported by the
finding that AS101 increases GDNF production in rat glomerular
mesangial cells (Kalechman et al., 2003) and GDNF mRNA levels in
peripheral blood leukocytes and head kidney cells (Okun et al.,
2006). AS101 is an immunomodulator (Sredni et al., 1987) that
directly inhibits the transcription of IL-10 followed by the increase
of specific cytokines including IL-1a and TNF-a (Sredni et al., 1987;
Kalechman et al., 1995, 1997; Strassmann et al., 1997). AS101
increases GDNF levels in rat astrocyte cultures and in the human
SVG astrocyte cell line, while LPS-induced IL-10 secretion in the
presence of AS101 is inhibited in both cell types (Sredni et al.,
2007). Moreover, inhibition of IL-10 by AS101, or its neutralization
by IL-10 neutralizing antibodies results in GDNF up-regulation in
primary astrocytes. Conversely, the addition of IL-10 inhibits GDNF
production (Sredni et al., 2007). In 6-OHDA-lesioned rats, GDNF
mRNA levels are greater in the substantia nigra of AS101-treated
rats compared to controls, whereas the levels of IL-10 mRNA and
protein were significantly lower in the AS101-treated rats (Sredni
et al., 2007). It should be stressed that the infusion of AS101 into
the substantia nigra using an osmotic minipump improves motor
function and sustains dopaminergic neurons in the 6-OHDA rat
model of PD, whereas its peripheral administration reduces MPTP-
induced damage to dopaminergic neurons and improves beha-
vioural outcome (Sredni et al., 2007). Given the ability of AS101 to
protect nigrostriatal dopaminergic neurons in animal models of
PD, namely by neurotrophic, anti-apoptotic and anti-inflammatory
mechanisms, it was proposed as a promising agent to treat PD
(Sredni et al., 2007). Since the effect of IL-10/AS101 does not seem
to be cell type-specifically regulated, it may explain the depriva-
tion of neurotrophic factors in several CNS diseases where elevated
expression of IL-10 is described (Vitkovic et al., 2001), although the
levels of pro-inflammatory agents are usually increased in those
diseases. The principal function of IL-10 appears to be limitation
and ultimately termination of inflammatory responses (Moore
et al., 2001). Therefore, the observation that AS101, which inhibits
IL-10 and induces pro-inflammatory molecules, increases GDNF
expression is consistent with the findings that pro-inflammatory
molecules induce GDNF up-regulation (Appel et al., 1997; Verity
et al., 1998, 1999; McNaught and Jenner, 2000; Remy et al., 2003;
Hashimoto et al., 2005c; Kuno et al., 2006).
Also type-2A protein phosphatases (PP) seem to negatively
regulate GDNF expression as GDNF levels increase upon their
inhibition (Verity et al., 1998). This effect might be related to the
activation of NF-kB since NF-kB activity is controlled largely by its
phosphorylation state. Therefore, both kinases and phosphatases
contribute to a given activation level. Indeed, several evidences
point to the involvement of PP2A in the regulation of NF-kB
activity. Recently, in a screen for phosphatases that modulate NF-
kB activity, co-immunoprecipitation studies identified associa-
tions of PP2Awith IKK and NF-kB (Li et al., 2006c). Moreover, other
studies report that up-regulation of PP2A activity and down-
regulation of NF-kB activation are related (Egger et al., 2003)
possibly because increased phosphatase activity is associated with
stabilization of the non-phosphorylated form and reduction in
nuclear binding of NF-kB (Yamashita et al., 1999). In addition,okadaic acid, an inhibitor of PP1 and PP2A, induces sustained
activation of NF-kB and degradation of the nuclear IkBa (Miskolci
et al., 2003), consistent with increased nuclear binding of NF-kB in
the presence of okadaic acid (Sontag et al., 1997; Yamashita et al.,
1999). Altogether, these results support that the negative
regulation of GDNF expression by PP2A can occur via inactivation
of NF-kB. In addition, also PP2B (calcineurin) seems to negatively
regulate GDNF expression since FK506, a PP2B inhibitor, induces
GDNF up-regulation and release (Section 7.5).
The expression of GDNF is also decreased in astrocytes by
treatment with glyceraldehyde-derived advanced glycation end-
products (Miyajima et al., 2005), and this might have relevance in
the context of the blood–brain barrier since GDNF reduces its
permeability (Igarashi et al., 1999).
HIV-1 glycoprotein 120 (gp120) causes neurotoxicity in the rat
striatum by reducing BDNF levels (Nosheny et al., 2004). Recently,
intrastriatal administration of gp120 was reported to induce
retrograde degeneration of nigrostriatal neurons, and to reduce
nigral GDNF, but not BDNF, immunoreactivity. The lack of effect of
gp120 on striatal GDNF suggest that gp120 may not affect GDNF
synthesis, but that decreased GDNF levels in the substantia nigra
may be due to a reduced transport from the striatum. It was
therefore proposed that dysfunction of the nigrostriatal dopami-
nergic system associatedwith HIVmay be caused by a reduction of
neurotrophic factor support induced by gp120 due to interference
with neurotrophic factor accumulation, release, or signalling
(Nosheny et al., 2006). However, the mechanism involved in the
gp120-induced GDNF reduced levels in the substantia nigra
remains to be elucidated.
In addition to molecules that induce or repress GDNF
expression, it is also important to know whether other molecules
might regulate the intracellular pathways activated by GDNF, and
thereby enhance or decrease its effects. For example, loss of the
receptor tyrosine kinase antagonist Sprouty1 causes defects in
kidney development in mice due to increased sensitivity of the
Wolffian duct to GDNF/Ret signalling resulting in the development
of multiple ureters and multiplex kidneys (Basson et al., 2005).
Recently, new players acting negatively on GDNF signalling were
described (Fig. 4). Lrig1, a transmembrane protein containing
leucine-rich repeats and Ig-like domains, interacts with Ret
thereby inhibiting its recruitment to lipid rafts, the binding to
the GDNF–GFRa1 complex, receptor autophosphorylation, and
MAPK activation in response to GDNF (Ledda et al., 2008). Growth
Arrest Specific 1 (Gas1) is a molecule involved in cell cycle arrest
and widely expressed during development, but also induced
during, and participating in, excitotoxic neuronal death (Mellstrom
et al., 2002). Interestingly, Gas1 shows high structural similarity to
the GFRa (Cabrera et al., 2006; Schueler-Furman et al., 2006).
Recently, Gas1 was shown to significantly inhibit GDNF-induced
phosphorylation of the Ret tyrosine 1062 in SH-SY5Y neuroblas-
toma cells, resulting in extensively reduced GDNF-induced Akt
activation (Lopez-Ramirez et al., 2008; Fig. 4). In contrast, Cabrera
et al. (2006) found that Gas1 binds Ret in a ligand-independent
manner, and sequesters Ret into lipid rafts leading to modified
signalling downstream Ret. This occurs through a mechanism
involving the adaptor protein Shc as well as ERK, ultimately
blocking Akt activation. Consequently, Gas1 induction compro-
mises Ret-mediated GDNF-dependent survival effects. However,
no changes in Ret phosphorylation were observed, possibly
because a general anti-phosphotyrosine antibody was used,
whereas Lopez-Ramirez et al. (2008) used a specific anti-Ret
phosphotyrosine 1062 antibody.
Summing up, the mechanisms of the repression of GDNF
expression and signalling are beginning to be uncovered. This
aspect of the neurotrophic factors field is actually very recent, and
A. Saavedra et al. / Progress in Neurobiology 86 (2008) 186–215206we are convinced that this topic will receive more attention in the
future.
10. GDNF, from regulation to function
In this section, we will focus on the mechanisms of GDNF-
induced neuroprotection in relation to the molecules that induce
its expression. Usually the reviews on GDNF emphasize its
neuroprotective/neurorestorative properties and therapeutic
potential. We will therefore take this opportunity to review and
pull together the mechanisms contributing to GDNF’s action.
GDNF up-regulation is observed after excitotoxic insults
(Section 4) or in response to pro-inflammatory molecules (Section
5.1). These observations are consistent with GDNF having
important anti-apoptotic and anti-excitotoxic actions. GDNF has
been shown to up-regulate Bcl-2 and Bcl-XL levels inmany distinct
injury models (Sawada et al., 2000; Ghribi et al., 2001; Cheng et al.,
2002; Lenhard et al., 2002; Kilic et al., 2005), resulting in a
reduction of caspase activation (Sawada et al., 2000; Ghribi et al.,
2001; Kilic et al., 2005). Consistentwith these results,many studies
report reduced number of lesion-induced TUNEL-positive cells in
the presence of GDNF (Ghribi et al., 2001; Hermann et al., 2001;
Zhang et al., 2001b; Jin et al., 2003; Ding et al., 2004; Dong et al.,
2007). GDNF also regulates the levels of X-linked inhibitor of
apoptosis (XIAP) and neuronal apoptosis inhibitory protein (NAIP;
Perrelet et al., 2002). Furthermore, GDNF has an anti-excitotoxic
effect on cortical neurons through the selective attenuation of
NMDA-induced excitotoxic neuronal death by reducing NMDA-
induced Ca2+ influx (Nicole et al., 2001). GDNF also down-regulates
the NMDA receptor subunit 1 (Bonde et al., 2003), and there are
evidences that GDNF increases the expression of glutamate
transporters in vitro and in vivo (Naskar et al., 2000; Bonde
et al., 2003; Delyfer et al., 2005; Koeberle and Bahr, 2008).
GDNF expression is also regulated by reactive oxygen/nitrogen
species (Section 9.7), and many observations support a role for
GDNF in protecting cells against free radicals-induced injury. GDNF
decreases 6-OHDA-induced oxidative stress and reduces the loss of
dopamine in the striatum and in the substantia nigra (Smith and
Cass, 2007). Moreover, in the presence of a GDNF antibody
dopaminergic cell viability decreases in substantia nigra H2O2-
treated cultures, showing that endogenous GDNF up-regulation in
response to H2O2 is able to protect dopaminergic neurons in
culture (Saavedra et al., 2006). Furthermore, in neuron-glia
substantia nigra cell cultures, GDNF up-regulation in response to
H2O2 down-regulates the expression of heme oxygenase-1, a
marker of oxidative stress (Saavedra et al., 2005). These observa-
tions are consistent with the finding that GDNF significantly
elevates the activity of superoxide dismutase, catalase, glutathione
peroxidase (Chao and Lee, 1999; Cheng et al., 2004), and the levels
of reduced glutathione (Onyango et al., 2005). Accordingly, GDNF
suppresses the accumulation of oxygen radicals in vitro (Irie and
Hirabayashi, 1999; Sawada et al., 2000) and in vivo (Cheng et al.,
2004). In addition, GDNF decreases NOS expression (Hermann
et al., 2001) and activity (Wang et al., 2002). These observations are
consistent with GDNF decreasing the oxidative damage to lipids,
proteins, and DNA (Dong et al., 2007).
GDNF expression increases in response to neurotransmitters
and is therefore regulated in an activity-dependent manner
(Section 4). At the same time, several works show that GDNF
contributes to synaptic transmission. GDNF enhances the excit-
ability of midbrain dopaminergic neurons by inhibiting A-type K+
channels, a fast action mediated by MAPK activation (Yang et al.,
2001). GDNF also potentiates the activation of Ca2+ channels and
excitatory transmission inmidbrain neurons (Wang et al., 2003). In
addition, it was reported that long-term treatment of neuromus-cular synapses with GDNF potentiates spontaneous and evoked
neurotransmitter release and facilitates Ca2+ influx by enhancing
Ca2+ currents, an effect mediated by the up-regulation of the Ca2+
binding protein frequenin (Wang et al., 2001a). GDNF increases the
synaptic efficacy of dopaminergic neurons in culture by promoting
the establishment of new functional synaptic terminals (Bourque
and Trudeau, 2000), and recently a role for GDNF signalling in
hippocampal synaptogenesis was described (Ledda et al., 2007).
Therefore, GDNF can also play a role in learning and memory
processes. In fact, increased GDNF levels are associated with
improved water maze performance in rats (Young et al., 1999),
whereas mice with a deletion of one copy of the GDNF gene show
impaired water maze performance (Gerlai et al., 2001). Moreover,
low GDNF expression may be involved in hippocampal dysfunc-
tions such as age-related learning impairment and neuronal death
observed in murine models of accelerated ageing (Miyazaki et al.,
2003). Recent findings support these observations since lentiviral
vector-induced GDNF expression in hippocampal astrocytes
improves cognitive deficits in aged rats (Pertusa et al., 2007).
Furthermore, GDNF infusion into the brain increases the prolifera-
tion of progenitor cells in the hippocampus (Chen et al., 2005c), a
process that as been associated with learning and memory
(reviewed by Leuner et al., 2006). Possibly, the increased
neurogenesis in response to dietary restriction, enriched environ-
ment or physical exercise (Lee et al., 2000, 2002; Kitamura et al.,
2006; Olson et al., 2006) can occur via increased GDNF expression,
as all these environmental manipulations were shown to regulate
GDNF expression (Section 6).
In summary, GDNF functions are determined by the molecular
context that induces its expression. Thus, one can envisage that by
knowing more about the regulation of GDNF expression it is
possible to uncover unknown GDNF functions.
11. Concluding remarks
The last years have registered increasing interest in the
application of neurotrophic factors to the therapeutic field, and
to neurodegenerative diseases in particular. PD is in list of
neurodegenerative diseases whose treatment with trophic factors
as been the focus of extensive research, including clinical trials
using GDNF and, more recently, neurturin (Peterson and Nutt,
2008). Several efforts are being made in order to overcome the
problems associated with the delivery, targeting, safety, and
distribution of trophic factors to the CNS. Lately, a new trend is
growing. Increasing attention is nowbeing payed tomolecules that
induce the endogenous expression of trophic factors, or enhance
their signalling, as alternative therapeutic options for PD. There-
fore, in addition to a therapeutic tool itself, GDNF constitutes also a
target for the development of new therapeutics.
In this manuscript we reviewed a large number of compounds
that trigger the endogenous GDNF synthesis and thus might
constitute useful targets to develop neuroprotective therapies for
PD. For many GDNF inducers the signalling pathway responsible
for their effects on GDNF expression is already uncovered, and this
issue was also addressed in this work. Among the compounds that
trigger the endogenous GDNF expression are the natural neuro-
transmitters that control the activity-dependent expression of
neurotrophic factors, which changes with the neurodegenerative
process. Many of the established and novel drugs for PD manage-
ment increase GDNF expression, namely several dopamine
receptor agonists and enhancers. The extent to which their
therapeutic effect is due to the control of symptoms or
neuroprotection is not clear yet. Neurotransmitters, like cytokines,
also mediate the neuron-glia cross-talk crucial in the response to
injury. Although some inflammatory players might be protective
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neurotrophic factors, it is widely accepted that controlling
inflammation is beneficial. This is because inflammation can
actively cause neuronal damage and death, and the microglial
response to neuronal damage results in a self-propelling cycle of
neuron death (reviewed by Block and Hong, 2005).
In this work we also discuss the contribution that, by inducing
the endogenous GDNF expression, herbal extracts from the
traditional medicine can bring to the neuroprotection of dopami-
nergic neurons, and as potential therapeutic tools for PD. More-
over, many of these compounds are able to attenuate the
degeneration of dopaminergic neurons, and the motor symptoms
in models of PD. Although the induction of GDNF expression has
not been addressed inmany cases, Chinese herbs or herbal extracts
may promote neuronal survival and neurite growth, and facilitate
functional recovery of brain injures by distinct mechanisms
(reviewed by Chen et al., 2007). They might therefore represent
an attractive choice for clinical trials with PD patients, so it is worth
to investigatewhether their trophic effects aremediated, or not, by
the up-regulation of GDNF expression.
Mounting evidence support the positive impact that a healthy
life style, including an appropriate diet, physical exercise and an
active social life, has on the expression of neurotrophic factors,
including GDNF. Therefore, this non-drug and non-invasive
approach to increase the endogenous GDNF expression may help
preventing the onset of degeneration or, in combination with
pharmacological treatments, reduce the severity of the motor
symptoms. Moreover, given its involvement in synaptic plasticity
and synaptogenesis, GDNF can play a role also in learning and
memory. One may therefore speculate that increasing the
endogenous GDNF expression would also contribute to fight the
cognitive decline observed in PD patients.
Another aspect focused in this review is a new perspective
about the biology of neurotrophic factors that is the negative
regulation of their expression, as well as the repression of their
intracellular signalling. However, we still have a great need to learn
further about this subject. Knowing more about the repression of
GDNF expression, and themechanisms that inhibit its intracellular
signalling, will prove beneficial to the understanding of patho-
physiological conditions, due either to increased or decreased
GDNF expression/signalling. We consider that this subject
deserves further attention in the upcoming future.
In summary, in this work we provide an overview of the
evidence showing that it is possible to manipulate the endogenous
GDNF expression, that this can have clinical implication for the
management of PD and prove to be useful as an alternative or a
complement to pharmacological or more invasive approaches. We
hope that this synopsis stimulates the research in the field of the
endogenous expression of trophic factors, mainly focused on the
potential therapeutic application to the treatment of neurodegen-
erative diseases.
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